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CHAPTER I 
 
Introduction 
 
 The vast majority of the mammalian genome does not encode a transcribed message. 
This noncoding portion of the genome was once considered to be “junk” DNA, but is 
now understood to be critically important to human health and gene regulation. The 
importance of non-coding DNA has been illustrated by three observations: Firstly, the 
majority of the conserved elements in the genome are noncoding, implying necessity for 
fitness. Secondly, the noncoding section of the genome is actively marked in cell-type 
and stimulus-specific patterns by covalent histone modifications, patterns of DNase 
hypersensitivity, transcription factor binding and binding of proteins critical for 
transcription such as polymerase II (Pol II). This observation implies a global importance 
for gene regulation. Thirdly, mutations in the noncoding sections of the genome are 
associated with wide ranging human and animal traits and deletion of non-coding 
elements has been mechanistically linked to gene regulation. These three observations 
have led to the belief that understanding the noncoding section of the genome will be 
critical for understanding both gene regulation and for understanding human diseases 
which results from noncoding mutations.  
 In metazoans, developmentally regulated genes are thought to require cis-regulatory 
elements for faithful developmental decisions. For example, the gene interferon gamma 
(IFNG) must be expressed in T helper (Th) 1 cells, but actively repressed in alternative 
Th lineages such as Th2 cells. Transgenic mice carrying an 8.6 kb transgene of the 
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human IFNG gene fail to properly repress IFNG in Th2 cells. However, transgenic mice 
carrying an 190 kb transgene do. This has led to the hypothesis that IFNG requires cis-
regulatory elements for proper developmental decisions.  Interferon gamma (IFN-γ) 
signaling is critically involved in the host defense against intracellular pathogens. 
Individuals and animals that have defects in IFN-γ signaling pathways develop severe 
immunodeficiency, often succumbing to mycobacterial infection (1). Common 
polymorphisms associated with IFN-γ signaling are associated with an increasingly large 
array of diseases such as coronary artery disease (2), cervical cancer (3) and ulcerative 
colitis (4). As such, understanding IFN-γ signaling and IFNG regulation is important to 
understanding human health. In addition, understanding IFNG regulation provides much 
needed functional understanding of the noncoding segment of the human genome.   
 
Distal regulation 
 
Human disease and noncoding segments of the genome 
 A variety of human genetic diseases, as well as everyday polymorphisms, result from 
mutations in distal regulatory elements (5). Also, the majority of trait associated 
polymorphisms by genome wide association studies (GWAS) reside in noncoding 
segments of the human genome (6). Specific examples of distal regulation and human 
disease include cis-regulatory regions which have been implicated in both the repression 
and activation of genes involved in human disease. For a gain-of-function example, a 
mutation 1 megabase from the Sonic Hedge Hog (SHH) promoter has been shown to 
cause preaxial polydactyly (7). In these individuals, too much SHH is expressed in the 
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developing limb bud and an extra thumb develops. For a loss-of-function example, 
mutations in beta globin or alpha globin loci distal regulatory elements have been linked 
to thalassemia (8, 9). This was first demonstrated in 1983 when a thalassemia patient was 
discovered to have a long-range deletion near the beta globin locus. This chromosome did 
not express beta globin, and had hallmarks of a “closed” chromatin state (CpG 
methylation and a lack of DNase hypersensitivity) (8). The thalassemia chromatin 
accessibility defect arises specifically in erythroid cells, showing human cis-regulatory 
elements provide cell-type specific chromatin accessibility (10). In transgenic murine 
models, the thassalemia defect was found to be a deletion of a locus control region (LCR) 
which is necessary for both high levels of expression and transgene-copy number 
dependent expression of a human β-globin transgene (11). Distal elements have also been 
implicated in oncogenesis. Some instances of Burkitt’s lymphoma result from a 
chromosomal translocation that causes an immunoglobulin heavy chain distal element to 
promote expression of the c-myc oncogene (12). Many other diseases have been linked to 
long-range elements (reviewed in ref (5)). As polymorphism analysis moves from 
analyzing just the core elements of a gene to analyzing the whole genome, many more 
will be characterized. 
 
 Long-range regulation 
 Arguably, the most intensely studied loci to date have been the alpha globin locus and 
the beta globin locus. Both of these loci contain multiple genes expressed in order during 
development, from the gene closest to the locus control region to the gene farthest away 
from the LCR (13, 14). The beta-globin LCR contains five DNase hypersensitivity sites 
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(six in the mouse) called 5’HS1-HS5. All of the five HS sites are necessary for tissue-
specific transcription, but each has unique sequence composition and function(s). For 
instance, 5’HS5 is thought to insulate the spreading of neighboring heterochromatin (15), 
while 5’HS2 alone is able to confer tissue-appropriate expression in vivo (16). Similarly 
in the alpha-globin locus, only one element, a hypersensitivity site 40 kb from the 
promoter (HS-40), has been shown to be able to enhance alpha globin expression in vivo 
(17).   
 In cell based in vitro transcription assays, locus control regions are position 
independent, but copy number dependent. However, in vivo both position and orientation 
of locus control regions are critical for proper expression (18-21). For example, inverting 
the sequence of the beta globin LCR abolishes all transcription from the locus (21). In the 
Hox gene model, the different genes in the locus are thought to compete for LCR 
enhancers during development. So, the closest genes are first looped into close proximity 
to LCR enhancers and are expressed earliest. Experimental removal of “spacer” genes 
from the Hox locus results in aberrant Shh expression (activated by late Hox genes) and 
deformed limb growth (22). The reports on how such distal elements establish higher 
order chromatin structure have not been conclusive. In the human growth hormone locus, 
a major control element, HS1, is necessary for histone acetylation and phosphorylated 
RNA pol II binding throughout the locus, but not chromosome looping (19, 23, 24). 
Histone tail acetylation across loci is associated with transcriptionally active loci. 
However, when a transcription termination site is placed between HS1 and the genes it 
regulates, looping and transcription is disrupted, but histone acetylation is not (19). For 
the alpha globin locus, deletion of the LCR in a humanized BAC model abolishes 
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transcription but not histone acetylation (25). This LCR deletion was intended to mimic 
that of a naturally occurring Spanish thalassemia patient with a “closed” chromatin state. 
However, when the actual chromosome from the patient was introduced into a mouse cell 
line, histone acetylation was still absent (26).  
 In a study associating expression variability with polymorphism distances, the 
strength of a promoter was found to be cell-type specific but also related to the distance 
from the regulated gene (27). However, developmentally regulated genes often have 
distal cis-regulatory elements located up to a megabase away from their transcription start 
site (7) or can even be located on different chromosomes (28). These distant regulatory 
elements are thought to function with the assistance of both intra- and inter-chromosomal 
interactions. In mammals, the protein CCCTC binding factor (CTCF) is thought to 
provide a variety of functions, including the capability to bind at multiple regions of the 
genome and to form chromatin loops (29). Formation of such complexes is facilitated by 
the ring-forming protein cohesin (30). A relevant question is the exact function of CTCF 
binding regions in the genome. CTCF has been described as a transcriptional activator 
(31), insulator (32) and a repressor (33). However, most of these functional results, 
especially insulator studies, come from reporter assay systems, which do not take 
genomic context into account. In a genomic context, experimental mutation of a CTCF 
site in the β-globin locus showed effects on chromatin looping and accessibility, but not 
on expression of the β-globin gene (34). Recently, from chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) data, CTCF peaks were found to separate active and 
repressive chromatin domains (35). However, this separation was found at only a small 
fraction of CTCF binding sites. In fact, barrier function may be achieved by association 
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with additional accessory effector proteins rather than by CTCF itself. As such, the 
functional role for specific CTCF binding sites remains to be determined.  
 
 The Histone Code 
 Eukaryotic DNA is wrapped around an octomer of a core comprising a heterodimer 
of four proteins: Histone 2A (H2A), H2B, H3 and H4. These histone proteins contain 
flexible N-terminal tails that are subject to post-translational covalent modification (36). 
These post-translational modifications form extensive reproducible patterns in a cell-type 
and stimulus-specific fashion leading to the hypothesis that there is a ‘histone code’ 
written and read as a means to orchestrate gene transcription (37, 38). Much work has 
gone into mapping histone tail modifications. A pattern has emerged which has allowed 
the classification of chromatin into several states based upon local histone modifications. 
In this model, mono-, di- and trimethylation of histone 3 lysine 9 (H3K9Me3), H3K9Me2 
and H3K27me1/2/3 are associated with transcriptional repression or silent enhancers 
(39). In contrast, most other histone marks, as well as the unstable histone variant H2A.Z, 
are associated with either transcriptional activation or active/poised enhancers and 
promoters. For example, a strong, active promoter is associated with the histone mark 
H3K4Me3, while a poised or weak enhancer is marked with H3K4Me1 (40). Similarly, 
the histone acetylation marks are associated with active gene areas. 
 In addition to mapping histone marks, substantial work has gone into understanding 
the proteins that read and write the ‘histone code.’ Histone acetyltransferases (HATs) 
such as Tip60 or p300 promote the acetylation of histones, while histone deaceacetylases 
(HDAC) such as HDAC6 remove histone acetylation marks. Histone methylation marks 
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have a unique set of enzymes involved in the formation and reading of the marks, such as 
G9a, which catalyzes formation of the repressive H3K9Me2 mark (41) and LSD1, which 
removes the H3K9Me2 histone mark (42). These observations have led to the hypothesis 
that the histone code is written and erased in response to developmental cues or in 
response to extracellular stimuli. Interestingly, upon transcriptional activation both HAT 
and HDAC recruitment is seen at active genes and enhancers, leading to the hypothesis 
that gene transcription is not only accompanied the accumulation of activating acetylation 
histone marks, but is accompanied by a balance between acetylation and deacetylation to 
achieve proper levels of transcription (43). Indeed, treatment with a histone deacetylase 
inhibitor promotes the transcription of poised genes, showing that histone deacetylase 
recruitment is a critical part of regulating gene transcription (44).   
  
Bacterial artificial chromosomes 
Bacterial artificial chromosomes represent a useful methodology to study cis-
regulation.  BAC technology involves the cloning of a large segment, up to 300 kb, of a 
genome into a bacterial artificial chromosome backbone. The BAC can then be used for 
sequencing, used as a large transgene, or other purposes. The particularly large size of the 
BAC is often thought to provide better protection against transgene integration effects 
when integrated into mammalian genomes, and also provides a sufficiently large template 
to encapsulate complete genomic loci (45). Further, because the initial mouse and human 
genomes were sequenced using BAC libraries, the sequences of individual BACs are 
typically known in advance. Growth of BAC transgenes in E. coli allows easy 
experimental manipulation such as the mutation or removal of a cis regulatory element, 
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changing order of cis regulatory elements, or altering distance between cis regulatory 
elements. This strategy of using BAC transgenes with or without cis-regulatory elements 
has been successfully employed in the study of numerous loci such as the beta-globin 
locus, the IL10 locus or the human growth hormone locus (46). Alternatively, BAC 
technology is commonly used as a method to analyze hard-to-detect proteins by replacing 
coding regions of genes with reporter genes (47) or to recreate transgenic viral genomes 
(48).  
Key observations about the nature of cis-regulation have been made using BAC 
transgenic animals. In initial studies of the beta-globin locus, BAC transgenes were used 
to define a locus control region as a region which provides a high-level of copy-number 
dependent and position independent expression (11). In later studies, examining 
individual cis-regulatory elements within the beta-globin LCR has expanded the function 
of individual LCR elements.  These studies demonstrate that individual cis-regulatory 
elements each have distinct roles in establishing chromosome accessibility, position-
independent expression, nuclear positioning and initiation of transcription (15, 26). BAC 
transgenic systems have also been critical in determining the functional outcomes of the 
removal of cis-regulatory elements from a gene locus. In studies of the HoxD locus, 
inclusion or removal of cis-regulatory elements results in tissue-specific loss of gene 
expression (49). In the same study, and in studies of the beta-globin LCR, inversion of 
cis-regulatory elements resulted in loss of BAC transgene expression, showing genomic 
order is critical for proper gene expression (21, 49).  
In addition to dissecting the roles of cis-regulatory elements, BAC transgenic systems 
have been used to examine species-specific expression patterns. In a key study of the 
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alpha-globin locus, a BAC transgene has been inserted into its proper genomic location 
by replacing the endogenous locus. In this study, expression of the human BAC transgene 
is cell-type specific and dependent upon cis-regulatory elements but expression levels are 
reduced to 40% of the expression level of the endogenous gene (50). Further, 
homozygous mice with the alpha globin BAC transgene knock-in were not viable. These 
results were interpreted as representing subtle differences in transcription factor usage 
across species, which give rise to critical outcomes in terms of proper levels of gene 
expression. In other models, use of BAC transgenes from alternate species gives rise to 
species-specific gene expression (49). For example, a puffer-fish BAC of the HoxD locus 
drives high-levels of tissue-specific expression but does not drive gene expression in the 
developing mouse limb bud. Approaches to determine species-specific tissue expression 
and the functional roles of cis-regulatory elements have been combined. Using tissue-
specific gene expression from BACs with varying species of origins, combined with cis-
regulatory element deletions, a mammal-specific Tbx4 cis-regulatory element has been 
determined. This regulatory element is non-essential for viable mice but is needed for 
proper limb formation. In comparison, a vertebrate-specific Tbx4 regulatory element was 
required for viability (51).    
 A key step in the use of BAC transgenes is the preparation and analysis of transgenic 
mice. Because of the particularly large nature of the BAC transgene, three problems arise. 
First, the large BAC plasmid shears easily. Parameters which determine stability and 
shearing of BAC transgenes negatively impact the rate of creation of transgenic pups. As 
such, improper buffer choice or improper BAC plasmid concentration negatively impacts 
successful creation of transgenic pups. However methods of purifying BAC transgenes, 
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such as cesium chloride or ion exchange columns, and physical characteristics such as 
BAC size do not correlate with the creation of successful transgenic mice (52). Second, 
because of the large size of the BAC plasmid partial integration effects are common (53). 
Because of the potential for partial integration effects, it is critical to check that 
transgenes have achieved full integration before lines can be analyzed. Proper integration 
can be easily checked by quantitative PCR.  Third, copy number and full-transgene 
genotype must be assessed throughout generations to ensure that independent association 
does not occur as a result of a recombination event.  
 
Interferon gamma 
 
CD4 cell development 
The adaptive immune system must respond to varying classes of challenges such as 
intracellular infections, infections by extracellular bacteria and fungi, infections by 
parasitic worms and autoimmunity. These responses are orchestrated by distinct lineages 
of CD4+ T cells termed Th1, Th17, Th2 and T regulatory cells (54). The primary 
function of the T helper cell is to “help” orchestrate the immune system to produce an 
appropriately tailored adaptive immune response, and elicit the same response for 
subsequent re-infections. This is achieved by creating T helper subsets, which produce 
tailored cytokine profiles.  These cytokines are, in turn, recognized by other cells in the 
immune system and body. Each cytokine profile has unique roles. For example, the Th2 
profile produces interleukin (IL)-4, IL-5 and IL-13. These cytokines are recognized by B 
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cells to promote antibody class switching to IgG1, IgE and IgA, and also by epithelial 
cells to promote the production of mucus and constriction.  
The Th1 response is characterized by the production of IFN-γ. IFN-γ is also produced 
by CD8+ cytotoxic T cells and natural killer (NK) cells.  Every nucleated cell in the body 
has an IFN-γ receptor, and the capability to signal through STAT1 upon IFN-γ 
stimulation. However, the downstream effects of STAT1 signaling vary with cell type 
and circumstances. IFN-γ signaling is most famous for its ability to activate macrophages 
to destroy phagocytosed cells, but IFN-γ can also elicit a pro-inflammatory response, halt 
cellular proliferation, promote expression of MHC molecules, promote nitric oxide 
production and promote class-switching to IgG subclasses. Most of these responses have 
the common effect of halting intracellular infections. Class-switching to IgG2 assists in 
opsonization of small immunogens, which allows for efficient complement fixation and 
efficient recognition by effector immune cells.  
The cytokine profile of the Th17 response is far more heterogeneous (54). Human 
Th17 cells are characterized by the production IL-17A and IL-17F, but can also produce 
IL-22 and IL-26 (55).  The production of IL-22 and IL-26 can also be made without IL-
17A/F by Th22 cells. However, a common response downstream of receptor ligation 
seems to be STAT3 signaling, which results in characteristic production of antimicrobial 
peptides and recruitment of neutrophils.  Human Th17 cells can also produce IFN-γ.  In 
human Th17 cells, IL-17 and IL-22 are preferentially expressed by IFN-γ negative cells 
while IL26 is preferentially expressed by IFN-γ positive, IL-17A negative cells (56). 
The developmental decisions of different T helper subsets stem from the instruction 
of cytokines received during T cell stimulation. For example, IL-12 is critical for Th1 
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differentiation by the signaling of STAT4 and subsequent upregulation of T-bet (57). In 
addition to IL-12 signaling, IFN-γ and IL-2 act as both autocrine and paracrine cytokines 
to promote Th1 development (58) by STAT1 and STAT5A/B signaling, respectively 
(59). Among other cytokines, IL-23 is critical for Th17 differentiation and inhibiting Th1 
differentiation by signaling through STAT3 (60). Although IL-23 is unique from IL-12, 
they share a common evolutionary ancestor (61). IL-12 and IL-23 are separate 
heterodimers, which share a subunit, IL-12p40. The other IL-12 and IL23 subunits are 
encoded on a common locus. The receptors for IL-12 and IL-23 also are separate 
heterodimers sharing one common subunit and a separate common locus.   
CD8+ cytotoxic T cells are an adaptive immune subset of the T cell lineage (Figure 1-
1). Like mature Th1 cells, mature CD8+ T cells are able to rapidly produce the cytokine 
IFN-γ upon stimulation with cognate peptide-loaded major histocompatability complex 
(MHC) or simultaneous stimulation with IL-12 and IL-18 (62). Unlike CD4 T helper 
cells, which recognize peptide presented in MHC class two, CD8 cells recognize peptide 
presented by MHC class one. MHC class one is expressed on every nucleated cell and, as 
such, the chief function of CD8 cytotoxic T cells is to recognize infected cells which are 
presenting peptide on their MHC class one. In addition to IFN-γ, CD8 T cells have other 
effector functions, such as production of perforin, granzyme B and the ability to directly 
signal apoptosis by Fas-Fas ligand interactions (63).  
CD4+ T helper T cells and CD8+ cytotoxic T cells develop from T cell precursors in 
the thymus microenviroment. In the thymus, both CD4+ and CD8+ subsets develop after 
successful recombination of both alpha and beta chains of the T cell receptor, allowing 
the recognition of distinct MHC-presented peptides by different T cell clones. A separate 
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branch of T cells, the natural killer T cell, also develops from a T cell precursor in the 
thymus, and has a semi-invariant T cell receptor which targets glycolipid antigens. Like 
conventional T cells, upon instruction in the periphery, the NKT cell can release 
cytokines such as IFN-γ. Outside of the T cell lineage, two main lines of lymphocytes 
develop in the bone marrow, natural killer cells and B cells. Natural killer cells exit the 
bone marrow microenviroment as innate immune cells, and are able to produce cytokines, 
such as IFN-γ, upon stimulation (64). B cells, like T cells, are adaptive immune cells, but 
do not have a principle role producing IFN-γ.  
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CLP
 
 
Figure 1-1. IFN-γ in lymphocyte cell differentiation. Lineages of the lymphocyte tree are 
shown as they relate to IFN-γ production. Cell types which are predominantly interferon 
gamma positive after activation are shown. Polarizing cytokines in T cell differentiation 
are shown to illustrate culture conditions. CP: Common precursor.  
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The interferon gamma gene locus 
        Interferon gamma is expressed in various cell types during the terminal stages of 
their differentiation processes in an activation-dependent manner. For example, when 
antigen-presenting cells stimulate naïve CD4+ T cells under Th1 conditions, these cells 
undergo a differentiation process resulting in an active interferon gamma locus (65). 
Shortly after initial stimulation there is a short period of diminutive IFN-γ expression in 
both Th1 and Th2 cells (28). After that point there is a period of one or two days without 
transcription followed by a burst of interferon gamma production only in the Th1 
polarized cells. After that point, antigenic restimulation, or stimulation with appropriate 
cytokines, will produce a rapid and robust interferon gamma response. Thus, following 
the initial stimulation, the Ifng locus undergoes an epigenetic modification, which allows 
more rapid and robust expression upon subsequent restimulations (66). During this 
transition, the Th1 locus develops long range histone marks associated with 
transcriptionally permissive areas of the chromatin, such as H4 acetylation, and develops 
a pattern of long-range DNase hypersensitivity (67, 68) . 
 During the primary stimulation, IL-12 stimulation triggers the transcription factor 
STAT4 to induce transcription of a second transcription factor, T-bet (65). T-bet is 
necessary and sufficient for Ifng expression in activated CD4+ T-cells (69). During the 
primary stimulation, Ifng activation is T cell receptor (TCR) dependent. TCR stimulation, 
along with stimulation through costimulation molecules, triggers the downstream 
transcription factors c-Rel (of the Nf-κB complex), AP-1 and NFAT (70). These three 
transcription factors stimulate Ifng transcription. During secondary stimulation, Ifng 
transcription can be stimulated by TCR engagement, or by IL-18 and IL-12 cytokine co-
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stimulation (71). IL-18 signaling through the adaptor molecule Myd88 triggers NF-κB 
activity (72).  
        The exact size of the human IFNG or mouse Ifng locus is unclear. In addition to the 
promoter, six regulatory regions have been well characterized (Figure 1-2). There are 
three sites within introns of IFNG known to have enhancer activity (68). The genomic 
region outside of the IFNG gene coding region contains numerous conserved noncoding 
sequences (CNS) that are marked with lineage-specific histone modifications (73). 
Because these sequences are conserved throughout evolution they should theoretically 
have regulatory function critical for fitness of the organism. Indeed, numerous CNS have 
been shown to regulate gene expression in reporter assays. Of the various mouse 
conserved noncoding sequences (mCNSs) implicated in regulating the mouse Ifng gene, 
the mCNSs at -22 kb, -6 kb, and +18-20 kb have been best characterized. Each of these 
three CNS has a distinct regulatory function. 
        Mouse CNS-22 is a T-bet binding element necessary for production of an Ifng-BAC 
transgenic Thy1.1 reporter gene in T-cells and natural killer cells (74). Mouse CNS-22 
functions as a strong T-bet dependent enhancer in luciferase based assay systems (67). 
The -22 kb site does not have a DNase hypersensitivity site in naïve CD4+ cells and is 
maintained in a histone-tail hypoacetylated state from a histone deacetylase bound to 
Sin3a (44). Upon Th1 polarization T-bet replaces Sin3a and the -22 kb site develops H4 
acetylation and a very strong hypersensitivity site. The site also develops histone marks 
associated with transcriptionally permissive chromatin in Th2 cells. Because the site 
contains a permissive chromatin environment in both Th1 and Th2 cells, and strongly 
reacts to T-bet in an activation-independent manner, it is theorized that mCNS-22 
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functions to create an environment favorable to transcription in Th1 cells. In contrast, it is 
not known if a similar function exists for the human equivalent of mCNS-22, CNS-16. 
        Mouse CNS-6 (also termed CNS1) possesses a DNase hypersensitivity site in naive 
T-cells (67), suggesting it is a site critical for early events in Ifng remodeling. The 
transcription factors T-bet, STAT5, NFAT1 and –theoretically- AP1 bind to the -6 kb site 
(75-77). Mouse CNS-6 is thought to play a role in an early event in T-cell differentiation: 
within 24-72 hours of Th1 cell development a Jak3-dependent cytokine signal, probably 
IL-2, stimulates recruitment of STAT5 to the CNS-6 site (76).  By 72 hours after Th1 
differentiation the chromatin containing CNS-6 has looped into the promoter, possibly 
explaining why T-bet is known to bind to both sites (78). An alternative hypothesis could 
be made based upon the observation that the chromatin loop does not occur until later in 
T cell development. In this model, mCNS-6 functions later in T cell development, which 
is made possible by the action of STAT5 early in Th1 cell development. How the -6 kb 
site functions in differentiated Th1 cells is unclear. In vitro promoter assays have been 
contradictory. Some reports show T-bet dependent enhancer activity (75), while some 
papers describe T-bet independent activity (67). Similarly, DNase hypersensitivity has 
(75) and has not (67) been reported at mCNS-6 in a differentiated Th1 cell. 
        Mouse CNS+18-20 (also called CNS2) is similar to mCNS-22 in that it does not 
develop DNase hypersensitivity until Th1 or Th2 polarization (67), suggesting a role after 
the initial differentiation signal. Unlike these other two well-characterized CNS elements, 
CNS+18-20 does not have intrinsic in vitro enhancer activity. Rather, mCNS+18-20 has 
been shown to augment enhancer activity of mCNS+6 (79). Along these lines, the 
chromatin containing mCNS+18-20 loops into the interferon gamma promoter upon Th1 
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differentiation (28).  From these data it appears mCNS+18-20 functions by enhancing the 
activity of mCNS-6 after the Th1 differentiation signal. If mCNS+18-20, or the human 
homolog at CNS+20 has an individual function remains to be determined.   
 In a naïve CD4+ T cell, the Ifng locus localizes to the peripheral portion of the 
nucleus, in close physical contact with the Il4 locus (28). This interaction of alternatively 
expressed genes has been deemed a “poised chromatin hub.” Upon Th1 stimulation the 
Ifng locus detaches from the Il4 locus, but remains in the nuclear periphery (80). This is 
in stark contrast to most mammalian genes which adopt a central location in the nucleus 
upon transcriptional activation (81). It is unknown if the Ifng locus occupies foci of active 
RNA polymerase II called “transcription factories” before or after Th1 stimulation.  
        The studies on different CNS within the interferon gamma locus suggest individual 
CNS have distinct regulatory functions, which come together to drive proper regulation 
of a gene. It is unknown how diverse the function of long-range regulatory regions may 
be. Studies on the Ifng locus have been largely descriptive, and the one study that deleted 
CNS-22 in vivo did not establish a mechanism by which this CNS functioned (74). How 
these individual CNS cooperate to drive cell-type specificity, proper histone 
modifications, nuclear localization and chromosomal looping, and transcription factor 
occupancy throughout the loci is unknown.  
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Figure 1-2 The IFNG locus. 
Alignments of the human IFNG locus were made between humans, dogs, mice, frogs and 
zebrafish using the UCSC genome browser. Relative locations of human CNS+20, CNS-
4, CNS-16 and CNS-30 are shown, as well as names for the mouse homologs and other 
names given to each CNS given in the literature. The mouse Ifng locus contains Iltifb, 
which is a full-length Il22 duplication. In addition, retrotransposed pseudogenes with 
homology to Cdc5l are shown annotated on the mouse genome. The zebrafish genome 
contains at least one interferon gamma duplication, ifng 1-1 (82). The predicted transcript 
si:ch211-266a5.12 shows high homology to ifng 1-2, but expression has not been 
determined in vivo. Green hash marks are conserved sequences between humans and 
listed species 
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  Interferon gamma and disease 
Interferon gamma signaling pathways are thought to be critically involved in the host 
defense against intracellular pathogens. Collectively, mutations resulting in a lack of 
interferon-gamma signaling are termed “interferon-gamma deficiency.” Commonly, 
interferon gamma deficiency is observed when the interferon gamma receptor is mutated, 
however mutations in STAT signaling pathways and the interferon gamma gene have 
been observed. Typically, interferon gamma deficiency is associated with susceptibility 
to mycobacterial infection (1) including disease and death from bacillus calmette-guerin 
(BCG), which is used as an attenuated vaccine to protect against Mycobacterium 
tuberculosis infection. In addition to susceptibility to mycobacterial infection, interferon 
gamma deficiency is associated with potentially fatal susceptibility to intracellular 
bacterial infections such as Listeria monocytogenes (83) as well as viral susceptibility, 
(84). Partial defects in interferon gamma signaling have been observed, and are again 
associated with BCG susceptibility and persistence of tuberculosis infection (85).  
 Evidence that IFN-γ is critical for murine health is, like for humans, overwhelming. 
Like humans with interferon gamma deficiency, mouse Ifng knockout models show 
susceptibility to Mycobacterium tuberculosis infection (86). Mice lacking interferon 
gamma are deficient in the host response to diseases other than viruses and intracellular 
bacteria. For example, interferon gamma knockout mice have altered immune responses 
to various cancers (87), and are susceptible to malarial infection (88). Another telling 
aspect of the relationship between interferon gamma and health are relationships made 
between murine models of autoimmunity and interferon gamma deficiency. In mouse 
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models, depletion of interferon gamma with neutralizing antibodies protects against 
colitis. However, in experimental systems where interferon gamma knockout CD4 cells 
are adoptively transferred into a host lacking T cells, colitis is maintained (89). These 
results suggest that interferon gamma is necessary for autoimmune colitis but that 
interferon gamma expression by CD4+ cells is not. As such, it is possible that interferon 
gamma produced by other lymphoid cells than CD4+ T cells contributes to disease 
pathogenesis. Interferon gamma knockouts have also been shown more susceptible to 
collagen-induced arthritis (90). As such, interferon gamma is clearly involved in 
autoimmune processes. In humans, an interferon gamma blocking antibody is safe and 
clinically effective in the treatment of Crohn’s disease, but trials have not met clinical 
end points (91, 92). As such understanding interferon gamma regulation and variation in 
humans and its role in human autoimmune diseases provides a promising therapeutic 
option.  
  
Specific Aims 
 
 Summary 
 Upon encounter with antigen a naïve CD4+ T-cell may be stimulated to differentiate 
into a Th1 cell or a Th2 cell. Th1 cells must express interferon-gamma (IFN-γ) while Th2 
cells must not. IFNG spans 5 kb of genomic DNA, but is surrounded by up to 200 kb of 
evolutionarily-conserved, non-coding sequences (CNS). An 8.6 kb IFNG transgene does 
not confer Th1/Th2 selectivity. By using a transgenic bacterial artificial chromosome 
model, we have demonstrated that the much larger 200 kb region is sufficient to confer 
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Th1/Th2 selectivity. It is unknown why IFNG requires 200 kb of regulatory sequences 
and space. We hypothesize that appropriate timing and quantity of IFN-γ production is 
regulated by the coordinated action of numerous distal regulatory sequences. The long-
term goal of this project is to determine how long-range distal elements regulate 
expression of a gene. The goal of this project is to determine the mechanism and function 
of IFNG distal regulatory elements. To address the above hypothesis and project goals I 
propose the following two aims: 
 
 Aim 1. To determine the necessary function of IFNG distal regulatory elements 
 Previous studies have identified multiple conserved noncoding sequences of the 
mouse Ifng locus which are sufficient for enhancer activity in cell-based assays. These 
studies do not directly address biology of the human IFNG locus or address necessary 
function in a genomic setting. Specifically, two hypothesizes could be made: One, all 
IFNG enhancers have the same necessary function; or two, each IFNG enhancer has a 
cell-type and stimulus specific necessary function. We hypothesize that multiple distal 
regulatory elements in the IFNG locus elements exist, in part, to accommodate cell-type 
and stimulus specific diversity. BAC transgenes will be created lacking CNS-77, CNS-
30, CNS-16, CNS-4 and CNS+20. BAC transgene expression will be measured from 
developing and mature CD4+ Th1 and Th2 cells, CD8+ T cells, NK cells and NKT cells 
under T cell receptor signaling conditions or IL-12 and IL-18 signaling conditions. The 
results of this aim will determine how multiple distal regulatory elements determine cell 
and stimulus specific selectivity of IFNG expression and provide insight into how the 
immune system coordinates proper cytokine expression across many cell types. 
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 Aim 2. To determine how distal regulatory elements determine covalent histone 
modifications 
 The interferon gamma locus develops cell-type specific covalent histone tail 
modifications, and recruits chromatin effector proteins in a cell-type and stimulus 
dependent manner. It is unknown if long-range distal elements are involved in, and 
regulate covalent histone modifications throughout the IFNG locus. Our preliminary data 
identify two distal elements which regulate interferon gamma transcription. Activating 
distal elements, such as CNS-30, are hypothesized to function in the recruitment of 
transcription factors to the IFNG locus, and to provide a chromatin environment 
permissive to gene expression. We hypothesize that distal regulatory elements establish 
the higher chromosomal structure of the IFNG locus. Chromatin immunoprecipitation 
(ChIP) will be used to determine the impact the BAC deletions have on histone 
modifications through the IFNG locus, as well as specifically testing the hypothesis that 
CNS-30 directs transcription factors to IFNG. The results of these experiments will 
elucidate how distal regulatory elements function to establish higher order chromatin 
structure. 
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CHAPTER II 
 
Distal regions of the human IFNG locus direct cell-type specific expression  
 
Abstract 
 
Genes, such as IFNG, which are expressed in multiple cell lineages of the immune 
system, may employ a common set of regulatory elements to direct transcription in 
multiple cell types or individual regulatory elements to direct expression in individual 
cell lineages. By employing a BAC transgenic system, we demonstrate that IFNG 
employs unique regulatory elements to achieve lineage specific transcriptional control. 
Specifically, a one 1-kb element 30 kb upstream of IFNG activates transcription in T 
cells and NKT cells but not NK cells. This distal regulatory element contains a Runx3 
binding site in Th1 cells, and is needed for RNA polymerase II recruitment to IFNG, but 
not absolutely required for histone acetylation of the IFNG locus.  These results support a 
model whereby IFNG utilizes cis-regulatory elements with cell-type restricted function. 
 
Introduction 
 
Cell lineage-specific gene expression is a central challenge of multi-cellular life. Cell-
type specific, developmentally regulated genes may be expressed in just one cell type or 
in multiple cell lineages. Developmentally regulated genes expressed in multiple lineages 
must be responsive to different arrays of stimuli, transcription factors, and chromatin 
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environments present in the varying cell types in which they are expressed. Conversely, 
expression must be actively restricted to appropriate cell lineages. In metazoans, lineage-
specific expression is thought to be conferred by the use of distal regulatory elements (93, 
94). However, mechanisms by which distal regulatory elements direct lineage specific 
gene expression are largely unknown. One possibility is that developmentally regulated 
genes employ a single common set of regulatory elements to direct transcription in all 
cell types expressing these genes. An alternate possibility is that genes employ unique 
cell-type specific distal regulatory elements to achieve cell-type specific expression.  
IFN-γ is a cytokine produced by select cells of the innate and adaptive immune 
system. IFN-γ is most notably produced by CD4+ T-helper 1 cells, but is also produced 
by CD8+ cytotoxic T cells, natural killer cells, Natural Killer T (NKT) cells, 
macrophages and dendritic cells. IFN-γ must not be transcribed in other cell types, such 
as Th2 cells, developing T cells, and cells outside the immune system. A multitude of 
transcription factors have been implicated in regulating Ifng, including T-bet, STAT4, 
Runx3, GATA3 and Hlx (59). The transcription factor T-bet is necessary and sufficient 
for production of IFN-γ by CD4+ T cells (69). CD8+ T cells and natural killer cells 
express a second T-box containing transcription factor called eomesodermin (95). 
Because of this second transcription factor, CD8+ T cells do not show the strict reliance 
on T-bet for Ifng transcription under in vitro conditions as do CD4+ T cells (96, 97). 
These differences in T-box proteins show that transcription factor regulation of Ifng 
varies among the different cell types which produce IFN-γ. 
Mice carrying an 8.6 kb human IFNG transgene express high levels of human 
IFN-γ in both Th1 and Th2 cells. Th2 cells should not express IFN-γ. In contrast, a 190 
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kb bacterial artificial chromosome transgene with the human IFNG gene, and 90 kb of 
both upstream and downstream sequences does recapitulate Th1/Th2 selective expression 
(98).  This indicates that one or more distal regulatory elements are critical for cell-type 
specific regulation of IFNG. Regulatory elements within the Ifng locus (67, 75, 79, 99), 
and other developmentally regulated loci (93), may exist within distal conserved non-
coding sequences. For example, a CNS located -22 kb from the mouse Ifng transcription 
start site (CNS-22) is critical for mouse IFN-γ production in T cells and NK cells (74). 
Other work has shown that the CNS within the Ifng locus acquire cell-type specific 
histone marks which correlate with IFN-γ expression in Th1 cells, and histone marks 
which correlate with repression in Th2 cells (59). However, these studies do not explain 
how distal regulatory elements within the Ifng locus confer cell-type specific expression. 
They also do not explain why Ifng possesses a large cis-regulatory region and requires 
numerous transcription factors for proper regulation. Because the IFNG promoter alone 
does not confer cell-type specific expression, we sought to determine if a single distal 
CNS within the IFNG locus dictates cell-type specific expression in all cell types 
expressing IFNG or if separate CNS are employed to direct IFNG transcription by 
distinct cell lineages.  
To determine the role of distal regulatory elements within the IFNG locus, we 
created transgenic mice carrying a 190 kb transgene of the human IFNG locus. Activity 
of the BAC transgene mirrored many aspects of regulation of the endogenous gene 
including Th1/Th2 selectivity and reliance upon T-bet and Stat4 for expression of human 
IFN-γ in CD4+ cells and CD8+ cells. To determine which regions of the 190 kb BAC 
transgene contain distal regulatory elements, we pursued an unbiased deletion strategy. 
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We created 4 new BAC transgenic mice with 40 kb deletions of upstream or downstream 
sequences of the IFNG locus. Using the larger deletions as a guide, we created BAC 
transgenic mice with 1 kb deletions of individual CNS. We found that a CNS located at -
30 kb, relative to the transcription start site, is necessary for human IFN-γ production in T 
cells and NKT cells, but not NK cells. This CNS binds the transcription factor Runx3 and 
is necessary to recruit RNA polymerase II (RNAP II) to IFNG in T cells, but not 
absolutely required for establishment of histone acetylation across the IFNG locus. 
Together these results show that distal CNSs of a human gene have cell-type restricted 
function.  
 
Materials and Methods 
 
Mice.  
C57BL/6, C57BL/6.Stat4 -/- mice were obtained from Jackson Laboratory (Bar 
Harbor, ME), bred in the Vanderbilt University animal facilities, and used between 4-5 
weeks of age. Tbx21 (T-bet) -/- mice have been previously described (69, 98). Research 
using mice complied with all relevant institutional and federal guidelines and policies. 
 
Cell Purification and Cultures.  
CD4+ and CD8+ T cells were purified from splenocytes by negative selection as 
previously described (98). Purified CD4+ or CD8+ T cells, 1 x 105 cells/ml, were 
stimulated with immobilized anti-CD3 (2C11, ATCC, Manassas, VA) and irradiated 
antigen presentation cells (1 x 106 cells). IL-12 (5 ng/ml) and anti-IL-4 (11B11, ATCC) 
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were added to cultures to generate Th1/Tc1 effector cells and IL-4 (5 ng/ml) and anti-
IFN-γ (10 μg/ml, R4-642, ATCC) were added to generate Th2/Tc2 cultures. Anti-IFN-γ 
was omitted from Th2 cultures used for ELISA assays. Assays were preformed at day 3 
to measure the primary response. To analyze the effector response, T cells were cultured 
for 5 days, harvested and re-stimulated with plate bound anti-CD3 alone, a mock 
treatment, 10 ng/ml IL-12, 10 ng/ml IL-18, or 10 ng/ml IL-12 and 10 ng/ml IL-18. Anti-
CD3 coated plates were prepared by treating tissue culture plates with a 10 μg/ml anti-
CD3 solution overnight at 4ºC.  Splenic CD8+ T cells were also purified from OT-1 
transgenic mice and stimulated with antigen peptide, irradiated spleen cells and IL-2 as 
outlined in the results section. NK cells and dendritic cells were isolated by negative 
selection and macrophages were isolated by positive selection using magnetic sorting 
(Miltenyi Biotech), according to manufacturer’s instructions. NK cells, macrophages and 
dendritic cells were stimulated as described in the text for 48 hours. For NKT cultures, 
5X105 splenocytes were stimulated with 100 ng/ml αGalCer (kindly provided by Laura 
Gordy). Cultures were harvested after 48 hours. IFN-γ assays were performed by ELISA 
with mAbs recommended by BD Pharmingen. 
 
Intracellular cytokine staining.   
T cells were harvested on day four and restimulated with 50 ng/ml PMA and 1 μM 
ionomycin for two hours followed by addition of GolgiPlug (BD) and culture for an 
additional four hours. For macrophage and dendritic cell experiments, mechanically 
disrupted spleens were stimulated with PMA/ionomycin for five hours, briefly 
resuspended in water to lyse red blood cells, and processed for intracellular cytokine 
28 
 
staining. Cells were washed twice in ice-cold FACS buffer (2% FCS, 0.1% NaN3 in PBS) 
and labeled with fluorescent antibodies as outlined in the results section for 30 minutes. 
Cells were permeabilized and fixed with Cytofix/Cytoperm (BD) according to the 
manufacturer’s instructions. Flow Cytometry experiments were performed in the VUMC 
Flow Cytometry Shared Resource.  The VUMC Flow Cytometry Shared Resource is 
supported by the Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt 
Digestive Disease Research Center (DK058404). T cell cultures were gated on CD4+ or 
CD8+ subsets for analysis.  
 
Preparation of transgenic reporter lines.  
The human IFNG BAC clone RPCI11-444B24 (Invitrogen, Carlsbad, CA) was 
moved into the EL250 E. coli strain to allow controlled recombination and FLP protein 
expression (100). To mediate deletions with the BAC, 50-nucleotide homology arms 
were designed to flank segments of the BAC. Long PCR primers containing 5’ homology 
arms were synthesized (Table 2-1) and used to PCR-amplify a bacterial tetracycline 
resistance cassette flanked by FRT sites as previously described (101). This created 
“deletion cassettes” that were transformed into recombination-competent EL250/BAC 
cells (100). Tetracycline-resistant colonies were screened by PCR across recombination 
junctions and restriction digests were performed to verify predicted recombinations for 
each BAC deletion. The cassette was deleted by inducing FLP expression, leaving behind 
only a 34-bp FRT sequences in place of the deleted material. Final verification of correct 
modification and absence of unwanted alterations occurring during the modification 
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process was confirmed by additional PCR analysis, restriction enzyme digestion and 
pulsed-filed gel electrophoresis, and direct BAC sequencing.   
 To prepare BAC clone DNA for microinjection, BACs were purified using 
Nucleobond Giga-prep columns (Clontech) followed by treatment with Plasmid Safe 
DNase to remove sheared DNA (Epicenter). The remaining circular BAC DNA was 
desalted using an Amicon 100 centrifugal filtration column. Transgenic mice were 
prepared by standard pronuclear injection using circular BAC DNA, which is effective 
for generating transgenic founders (101). Positive founder mice were identified by PCR 
analysis of tail DNA using appropriate primers for the human IFNG gene. We also used 
PCR with human-specific primers at various points across the human IFNG BAC 
sequence to verify that all regions of the BAC transgenes were still present after 
integration into genomic DNA. 
 
Chromatin Immunoprecipitation.  
ChIP assays were preformed according to Millipore’s online protocol with minor 
variations: cells were harvested by centrifugation; each protein A Agarose-
antibody/chromatin wash was performed two times for ten minutes each and DNA was 
isolated by phenol-chloroform extraction. Immunoprecipitations were performed using 
either an anti-acetyl H4 antibody (Upstate 06-866), anti-H3k9Me2 (ab-1220), anti-Pol II 
(SantaCruz Biotech 899X), anti-Runx3 (Active Motif 39301) or normal rabbit IgG 
control. Significance by ANOVA was determined using PrismGraph software. For 
determining significance at specific genomic locations, a student’s t-test was preformed 
with Bonferroni’s inequality applied to the calculated probability.   
30 
 
Results 
 
Stat4 and T-bet dependence of reporter gene expression in T cells 
To initiate these studies, we examined activity of the 190 kb IFNG-BAC transgene in 
wildtype, Stat4 -/- and Tbx21 -/- CD4+ T cells. CD4+ T cells were cultured for three days 
with plate bound anti-CD3 under Th1 or Th2 conditions (primary stimulation). To 
measure secondary, effector responses, cells were cultured for five days, harvested and 
restimulated with plate bound anti-CD3 alone for an additional two days. We found that 
absence of either Stat4 or T-bet markedly reduced the activity of the IFNG-BAC 
transgene in Th1 cells during either primary or secondary, effector responses (Figure 2-1, 
left panel). Production of human IFN-γ by BAC transgenic CD4+ T cells was reduced by 
T-bet or Stat4 deficiency to a similar degree as production of murine IFN-γ (Figure 2-1, 
right panel). These results demonstrate that the IFNG-BAC transgene exhibits the same 
critical T-bet and Stat4 requirements for activity in the CD4 T cell lineage, as does the 
endogenous Ifng gene.  
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Figure 2-1 Expression of human IFN-γ from a 190 kb IFNG BAC reporter transgene in 
CD4+ T cells is Stat4 and T-bet dependent.  
Transgenic CD4+ T cells from C57/BL6 (Wt), C57/BL6.Tbx21 -/- (T-bet -/-), or 
C57/BL6.Stat4 -/- mice were cultured under Th1 or Th2 conditions for three days 
(primary stimulation) or five days. After 5 days, cultures were harvested and re-
stimulated with plate-bound anti-CD3 only for 2 days (secondary stimulation). Levels of 
human IFN-γ (left panel) and of murine IFN-γ (right panel) were determined by ELISA. 
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 To determine if the 190 kb IFNG-BAC transgene displays cell-type specific 
dependence upon the transcription factor T-bet, we next examined its expression in CD8+ 
T cells. We cultured wildtype, T-bet -/- and Stat4 -/- BAC transgenic CD8+ T cells with 
anti-CD3 and antigen presenting cells under Th1 or Th2 polarizing conditions. Similar to 
CD4+ T cells, absence of Stat4 reduced the ability of CD8+ T cells to produce human 
IFN-γ. Unlike the CD4+ T cells, transgenic CD8+ cells were able to produce human IFN-
γ in a T-bet -/- background (Figure 2-2A). These results are consistent with our earlier 
observations that T-bet does not influence endogenous IFN-γ production in CD8+ T cells 
that have been stimulated by polyclonal activation with anti-CD3 (65, 95, 102). T-bet -/- 
CD8+ T cells stimulated in vivo, or in vitro with antigen specific stimulation produce 
significantly reduced amounts of IFN-γ when compared to WT CD8+ T cells (96, 97). 
IFNG-BAC transgenic mice were backcrossed onto either wild type OT-1 TCR or T-bet -
/- OT-1 TCR backgrounds. CD8+ T cells were stimulated with the OT-I ovalbumin 
peptide, SIINFEKL, antigen presenting cells and IL-2 for five days. After five days, 
cultures were harvested and restimulated with SIINFEKL peptide and irradiated spleen 
cells. Cultures were harvested 2 days later and levels of human and murine IFN-γ were 
determined by ELISA. Under this antigen-specific stimulation, transgenic CD8+ T cells 
produced markedly reduced levels of murine and human IFN-γ in the T-bet deficient 
background (Figure 2-2B). Taken together, these results demonstrate that the IFNG-BAC 
transgene exhibits the same Stat4 and T-bet dependency as the endogenous Ifng-gene in 
CD8+ T cells.  
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Figure 2-2 Regulation of IFNG-BAC transgene activity in CD8+ T cells.   
(A) CD8+ T cells were purified from IFNG BAC positive wild type, Stat4 -/-, or T-bet -/- 
mice and were cultured under Th1 or Th2 polarizing conditions as in Figure 1. Cultures 
were harvested after 3 d (primary responses) or 2 d after re-stimulation with anti-CD3 
(effector responses) and were analyzed for levels of human or mouse IFN-γ by ELISA. 
(B) CD8+ T cells were also purified from IFNG BAC positive wildtype or T-bet -/- OT-I 
TCR transgene positive mice and stimulated with peptide antigen, APC and IL-2. After 5 
d, cultures were harvested and re-stimulated with peptide and APC.  After an additional 2 
d, cultures were harvested and IFN-γ ELISA assays performed. 
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Taken together, our results demonstrate that the IFNG-BAC transgene is sufficient to 
direct a) high level expression, b) antigen-induced expression, c) T-bet and Stat4 
dependency, and d) T1/T2 selective expression of human IFN-γ. Importantly, our results 
demonstrate that the IFNG-BAC transgene recapitulates key regulatory features of Ifng 
transcription. To identify key distal regulatory elements within the IFNG-BAC, we next 
performed a deletion analysis of the IFNG-BAC.    
 
40 kb regulatory regions within the 190 kb IFNG BAC transgene 
To identify elements within the 190 kb BAC transgene essential to drive faithful 
production of human IFN-γ, we first pursued an unbiased deletion strategy. Positions of 
individual conserved non-coding sequences within the 190 kb IFNG locus are shown in 
figure 2-3. While the distance between each CNS varies slightly among species, the order 
of individual CNS across the locus is absolutely conserved (Figure 2-3 bottom). It is 
unknown how many CNSs across the 190 kb locus participate in regulating IFNG 
transcription. We divided the transgene into four ~40 kb blocks for analysis, Δ1-4 (Figure 
2-3, Table 2-1). We constructed four deletions in the BAC representing each of these 40 
kb blocks, and prepared transgenic mice. We prepared a fifth 80 kb BAC deletion lacking 
the Δ3/4 region (Figure 2-3). We were able to leave the human homologs to mouse CNS-
22 (74), CNS-6 (37, 75) and CNS+18-20 (79), which have been studied in various 
reports, in the undeleted region. This way all deletions resulted in removal of novel 
regulatory elements.  
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Figure 2-3 Deletions made in this study.  
Positions of 40 kb deletions from the IFNG-BAC transgene are shown: red ∆1, green ∆2, 
blue ∆3, black ∆4, and small 1 kb CNS deletions, brown ∆-77, purple ∆-30.  Relative 
positions of human IFNG, Il26, and Il22 in the IFNG-BAC transgene are shown below.  
Evolutionary Mouse-Human sequence conservation, locations of CNS (red, > 70% 
sequence conservation between mouse and human spanning ≥ 200 bp) and locations of 
transposons (green) within the 190 kb human IFNG-BAC transgene as identified using 
the dcode website (www.dcode.org). 
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Table 2-1. Deletion locations 
The locations of the BAC deletions, and the entire BAC transgene are presented bellow. 
Note: Fig 2-3 is “flipped” in regard to absolute genomic location, so that the beginning of 
the IFNG gene appears on the left of the figure. Genomic locations are based on March 
2006 (NCBI36/hg18) assembly. 
 
 
 Deletion Location 
190 kb BAC chr12:66740833-66931792 
Δ1 chr12:66740833-66775765 
Δ2 chr12:66775767-66814449 
Δ3 chr12:66857579-66895638 
Δ4 chr12:66895640-66931792 
Δ-30 chr12:66869614-66870500 
Δ-77 chr12:66917565-66918546 
IFNG chr12:66834817-66839788 
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To determine which 40 kb blocks regulate IFNG transcription, CD4+ T cells 
harboring the different transgenes were cultured under Th1 or Th2 conditions. Cultures 
were harvested after primary or secondary stimulation and human and murine IFN-γ 
levels were determined by ELISA. Removal of Δ1 (+59 kb to +93 kb relative to the 
human IFNG transcriptional start site) or Δ2 (+20 to +59 kb) did not affect human IFN-γ 
production by either primary or effector CD4+ T cell cultures (Figure 2-4A). In contrast, 
the Δ3/4 (-92 to -18 kb) deletion caused a dramatic loss of human IFN-γ production after 
primary stimulation, and a complete loss of human IFN-γ production after secondary 
stimulation of effector cell cultures (Figure 2-4B). Results for Δ3 (-56 to -18 kb) mice 
were similar to Δ3/4 mice (not shown), and as such Δ3/4 mice were analyzed further, 
rather than Δ3 mice, to rule out cooperativity effects between the truncated, non-
expressed IL22, and its regulatory elements, and IFNG regulatory elements. Deletion of 
only Δ4 (-92 to -56 kb) resulted in an increase in human IFN-γ production in both 
primary and effector cell cultures (Figure 2-4B). Levels of murine IFN-γ were unchanged 
in cultures with the different BAC transgenes (Figure 2-4C). We also determined human 
and mouse IFN-γ levels by ELISA from CD8+ T cells cultured under Ct1 or Ct2 
conditions. Like CD4+ T cells, deletion of Δ4 resulted in an increase in human IFN-γ in 
both primary and effector CD8+ cell culture supernatants (Figure 2-4D). The Δ4 deletion 
removed the IL26 gene, which is a pseudogene in the mouse, and the 3’ end of IL22 
contained on the IFNG-BAC.  
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Figure 2-4 Functional consequences of large 40 kb deletions from the 190 kb human 
IFNG-BAC transgene.  
(A-D) Transgenic CD4+ T cells were cultured under Th1 or Th2 conditions as in figure 1. 
(A) Human IFN-γ levels were determined for IFNG-BAC, Δ1 and Δ2 CD4+ T cells, (B) 
determined for IFNG-BAC, Δ3/4 and Δ4 CD4+ T cells or (C) murine IFN-γ levels were 
determined for IFNG-BAC, Δ3/4 and Δ4 CD4+ T cells. (D) IFNG-BAC, Δ3/4 and Δ4 
CD4+ T cells were cultured under Th1 conditions for three days and mRNA levels were 
determined by quantitative PCR. Data points represent results of independent 
experiments. (E) CD8+ T cells were cultured under Tc1 or Tc2 conditions as in Figure 2 
and human IFN-γ levels were determined by ELISA. (F) Freshly isolated NK cells were 
stimulated with nothing, IL-12, IL-18, or IL-12 + IL-18. After 48 hours culture IFN-γ 
levels were determined by ELISA. (G) IFNG-BAC or Δ3/4 BAC transgenic splenocytes 
were stimulated with αGalCer for two days. IFN-γ levels were determined by ELISA. 
(All except D) Results are averages of at least three independent experiments. Error bars 
are s.e.m. * p < 0.05 
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To observe the effect of these deletions at the transcript level, we verified our 
results by quantitative PCR of cDNA made from day three Th1 cultures (Fig 2-4E). 
Taken together, these results identify two novel 40 kb regions which regulate IFNG 
transcription in T cells. The -56 to -18 kb region contains elements necessary for human 
IFN-γ production, while the -92 to -56 kb region represses IFNG transcription.  Notably, 
none of these large deletions resulted in increased production of human IFN-γ in Th2 
cells. This phenotype is predicted based upon observations that mice carrying only an 8.6 
kb IFNG transgene fail to repress human IFN-γ in Th2 cells (98). These results suggest 
that additional regulatory element(s) exist within the undeleted regions, -18 kb to +20 kb 
from the IFNG transcription start site, which govern Th1/Th2 selectivity.  
 
The -92 to -18 kb region is dispensable for IFN-γ production in innate immune cells 
To determine if function of regulatory regions within the -92 to -18 kb region is T cell 
specific, we isolated NK cells from BAC transgenic mice or Δ3/4 BAC transgenic mice 
and stimulated them with IL-12 and IL-18. To our surprise, in contrast to Δ3/4 BAC 
transgenic effector Th1 and Tc1 cells, Δ3/4 BAC transgenic NK cells robustly produced 
human IFN-γ (Figure 2-4F). To determine if dependence upon the -92 to -18 kb region is 
T cell intrinsic, regardless of expression of NK cell receptors, we examined human IFN-γ 
expression in Natural Killer T (NKT) cells. NKT cells are cells of the T cell lineage 
which express a semi-invariant T cell receptor, express natural killer cell surface markers 
and respond to glycolipid antigens (103, 104). NKT cells are the sole cell population 
stimulated by the NKT cell ligand alpha-galactosylceramide (αGalCer). Δ3/4 or BAC 
transgenic splenocytes were stimulated with the NKT cell ligand αGalCer. After two 
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days, human IFN-γ levels were determined. BAC transgenic, but not Δ3/4, NKT cells 
produced human IFN-γ in response to αGalCer (Figure 2-4G). Taken together, these 
results demonstrate that the -92 to -18 kb region is necessary in T cells and NKT cells, 
but not necessary in innate immune cells such as NK cells.  
 
CNS-30 is necessary for human IFN-γ production by T cells 
Having identified two large distal regions within the human IFNG-BAC transgene 
that differentially regulated IFNG transcription, we sought to identify specific CNS 
within these regions that recapitulated regulatory properties of these larger genomic 
regions. To identify the regulatory element responsible for the loss of human IFN-γ 
production seen in Δ3/4 BAC transgenic T cells, we focused on a conserved noncoding 
sequence located at -30 kb (CNS-30) from the IFNG promoter. The mouse homolog of 
CNS-30, located in the mouse genome at -34 kb, becomes histone acetylated in T cells, 
but not in freshly isolated NK cells and cultured NK cells. We examined mouse CNS-34 
for conserved binding sites for transcription factors known to regulate Ifng. We identified 
two conserved AML (also known as Runx) binding sites within the CNS. Runx3 has been 
shown to be necessary for sufficient Ifng production in T cells (105), but not necessary 
for Ifng production in NK cells (106). To verify Runx3 binding to CNS-34, we cultured 
CD4+ T cells for three days under Th1 or Th2 conditions and preformed chromatin 
immunoprecipitation (ChIP). We observed Runx3 binding predominantly to mouse CNS-
34 and to the Ifng promoter in CD4+ Th1 cells (Fig 2-5A). Considering these properties, 
we reasoned that CNS-30 may be the site within the -56 to -18 kb region required for 
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efficient IFNG transcription. We prepared a new BAC construct harboring a 1 kb deletion 
of a CNS-30 and produced new transgenic mice (Δ-30, Figure 2-3).  
 
 
 
 
 
Figure 2-5. CNS-30 is necessary for human IFN-γ production by T-cells.  
Cells were cultured from IFNG-BAC, Δ3/4 BAC or Δ-30 BAC transgenic mice. (A) 
CD4+ T cells were cultured for three days under Th1 or Th2 conditions and processed for 
ChIP assays with antibodies specific for Runx3 or IgG. Values for IgG controls were 
subtracted from means. (B) CD4+ T cells were cultured under Th1 or Th2 polarizing 
conditions. Levels of human and mouse IFN-γ were determined by ELISA. (C) Effector 
Th1 cells were stimulated with nothing, IL-12, IL-18, or IL-12 + IL-18. After 48 hours 
culture IFN-γ levels were determined by ELISA. (D) CD4+ and CD8+ T cells were 
cultured for four days under Th1 conditions, restimulated with PMA/Ionomyocin and 
analyzed for intracellular cytokine staining. Cells are gated on CD4+ or CD8+ 
populations. Results of individual experiments are shown.  
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 Δ-30 or IFNG-BAC CD4+ and CD8+ transgenic cells were cultured for primary and 
secondary stimulation as described above. We observed a dramatic reduction in human 
IFN-γ production by Δ-30 T cells in both the primary and the secondary Th1 cultures 
(Figure 2-5B). We next determined if CNS-30 had an agonist-specific role. We harvested 
day 5 effector Th1 cells and restimulated them with either plate bound anti-CD3 or IL-12 
and IL-18. Loss of human IFN-γ was evident in effector Th1 cells stimulated with anti-
CD3 and cells stimulated with IL-12 and IL-18 (Figure 2-5C). Our results were not due to 
differences in culture conditions as murine IFN-γ levels were unchanged (Figure 2-5 B, 
C). We next sought to distinguish if CNS-30 regulated the percentage of T cells which 
became IFN-γ producers, and thus by definition Th1 cells, or the amount of IFN-γ 
produced on a per-cell basis. We restimulated day four Δ-30 or IFNG-BAC Th1 cells 
with PMA/Ionomyocin and measured mouse and human IFN-γ levels by intracellular 
cytokine staining (Figure 2-5D). The Δ-30 deletion reduced the overall percentage of 
CD4+ T cells that became human IFN-γ positive. As such, our data indicated that CNS-
30 is necessary for human IFN-γ production in Th1 cells in response to both T cell 
receptor stimulation and IL-12 and IL-18 costimulation.  
 
CNS-30 is dispensable for IFN-γ production in innate immune cells 
We next isolated NK cells from BAC transgenic mice or Δ-30 BAC transgenic mice 
and stimulated them with IL-12, IL-18 or a combination of both cytokines. Like 
transgenic NK cells lacking the Δ3/4 (-92 to -18 kb) region, Δ-30 natural killer cells were 
able to robustly produce human IFN-γ (Figure 2-6A).  We also measured IFNG mRNA 
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levels in CD4+ Th1 cells after TCR stimulation and NK cells after IL-12 and IL-18 
stimulation. We observed a ten-fold reduction of human IFNG mRNA in Δ-30 T-cells, 
relative to IFNG-BAC transgenic T cells, but equivalent production of IFNG mRNA by 
NK cells from the two transgenic lines (Figure 2-6B). These results demonstrate that 
CNS-30 is a regulatory element necessary for human IFNG transcription in T cells, but is 
dispensable for transcription in NK cells. 
Natural killer cells are members of the innate immune system which arise from the 
lymphoid cell lineage. To determine if CNS-30 was necessary for sufficient IFN-γ 
production in innate immune cells of the myeloid cell lineage, we examined human IFN-γ 
expression in macrophages and dendritic cells. For macrophage isolation, we purified 
CD11b+ cells and for dendritic cell isolation we purified CD11c+ cells.  Δ-30, Δ3/4 and 
BAC transgenic CD11b+ and CD11c+ cells were isolated and stimulated with IL-12 and 
IL-18. Like natural killer cells, transgenic Δ-30 and Δ3/4 CD11b+ and CD11c+ cells 
were able to produce human IFN-γ at levels comparable to the complete IFNG-BAC 
transgenic controls (Figure 2-6C). We purified CD11c+, CD8+ cells and measured 
supernatant IFN-γ levels after 48 hours of IL-12 and IL-18 stimulation. We did not detect 
human IFN-γ in these culture conditions. Human IFN-γ expression in our ex vivo culture 
assay was stimulation dependent, and we did not observe spontaneous IFN-γ production.  
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 Figure 2-6 CNS-30 is not necessary for human IFN-γ production in NK cells, 
macrophages and dendritic cells 
(A) Freshly isolated NK cells were stimulated with nothing, IL-12, IL-18, or IL-12 + IL-
18. After 48 hours culture IFN-γ levels were determined by ELISA. (B) IFNG-BAC and 
Δ-30 CD4+ T cells were cultured under Th1 conditions for three days (left panel) or NK 
cells were cultured for two days with IL-12 and IL-18 (right panel) and mRNA levels 
were determined by quantitative PCR. Data points represent results of individual 
experiments. (C) Freshly isolated macrophages or dendritic cells were cultured for two 
days stimulated with nothing, or with IL-12 and IL-18 and culture fluids were harvested 
and analyzed for IFN-γ levels by ELISA. Results are averages of at least three 
independent experiments. Error bars are s.e.m. (D) Whole spleen was stimulated with 
PMA/Ionomyocin and analyzed for intracellular cytokine staining.  
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To determine which CD11b+ and CD11c+ cell populations produced human IFN-γ, 
we stimulated IFNG-BAC, Δ3/4, Δ-30 and non-transgenic splenocytes with 
PMA/Ionomyocin and determined human and mouse IFN-γ expression by intracellular 
cytokine staining. After excluding dead cells by forward and side scatter, we 
characterized cell populations based on MHC II, B220, CD11b, CD11c and F4/80 
staining (Figure 2-6). The NK1.1 surface marker was not used to distinguish NK cells 
because these experiments were performed on a BALB/C background. Among CD11b+ 
and CD11c+ populations, IFN-γ expression was low in MHC II+ dendritic cell and 
macrophage populations. However, human IFN-γ was detected among MHC II-, 
CD11b+, CD11c+, B220- and MHC II-, CD11b+, CD11c-, B220-, F4/80+ populations 
(Figure 2-8D). These MHC II- populations have been described as an IFN-γ producing 
NK cell subset (107). Unlike CD4+ and CD8+ T cells, in which human IFN-γ was almost 
always co-expressed with mouse IFN-γ (Figure 2-5D), human IFN-γ expression in 
CD11b+ and CD11c+ cells was predominantly in the mouse IFN-γ negative cell 
population. Human IFN-γ staining was comparable between IFNG-BAC and Δ3/4 
CD11b+ and CD11c+ cells. Thus, unlike T cells and like NK cells, CD11b+ and CD11c+ 
cells do not require either CNS-30 or the larger Δ3/4 genomic region for sufficient IFN-γ 
production. 
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Figure 2-7 Intracellular cytokine staining (A) (Left) Representative data for 
intracellular cytokine staining in Figure 2-6. After red blood cell lysis and 
PMA/Ionomyocin stimulation, whole splenocytes were subject t o intracellular 
cytokine staining. Cells were gated on B220, MHC II, F4/80, CD11b and CD11c. 
IFNG- BAC splenocytes are used as the example cell population. (B) Representative 
cell purities for ex vivo cultures used in Figure 2-5C 
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Copy Number Variation 
 
We also determined if human IFN-γ production varied with relative transgene copy 
number. We assessed transgene copy number by standard techniques using quantitative 
PCR and genomic primer pairs positioned across both the human BAC transgene and the 
endogenous murine locus in the different transgenic lines. Because we did not have 
variation in copy number between IFNG-BAC transgenic lines, we selected mice 
carrying an IFNG-BAC transgene where we had removed CNS-77 (Δ-77). We selected 
Δ-77 BAC transgenic lines for our analysis since these had the greatest variation in 
transgene copy number (Figure 2-8). Since we were unable to determine absolute copy 
number by this approach, results are expressed as copy number relative to the IFNG-BAC 
transgenic line. Flow cytometry and intracellular cytokine staining were employed to 
determine levels of human and murine IFN-γ producing cells in Δ-77 BAC transgenic 
CD8+ T cells cultured under Th1 polarizing conditions from three separate founder lines. 
This analysis demonstrated that, among the three Δ-77 BAC transgenic lines, human 
IFN-γ production by the Δ-77 BAC transgenic lines was proportional to transgene copy 
number.   
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Figure 2-8 Copy number dependent expression 
(A) Relative copy number of three different -77 lines was determined by quantitative 
PCR analysis of genomic DNA. CD8+ T cells were cultured for 4 days under Th1 
polarizing conditions and were analyzed for IFN- levels by intracellular cytokine 
staining. Cells were gated on CD8+ cell populations. (B) Replicates were subjected to a 
linear regression analysis. 
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CNS-30 is required for RNAP II recruitment, but not histone acetylation 
In eukaryotes, DNA is wrapped around packaging histone proteins. These histones 
are subject to a series of enzymatically-catalyzed chemical modifications that produce a 
‘histone code’ of epigenetic information above the genetic code (38). In mice, CNSs 
within the Ifng locus are marked by histone-4 tail acetylation (H4Ac) during Th1 
development by a Stat4 and T-bet dependent mechanism (44, 59, 73, 77, 108). H4Ac is 
correlated with transcriptionally permissive areas of chromatin (37). To determine if the 
human IFNG-BAC transgenic locus also acquired H4Ac marks and the role of distal 
regulatory elements within the Ifng locus in establishing the histone code, we cultured 
CD4+ T cells from BAC transgenic mice for three days under Th1 conditions and 
performed ChIP assays. Under these conditions the endogenous mouse locus developed 
extensive, long-range H4Ac marks (Figure 2-9). We were able to detect H4Ac marks 
across the human locus in IFNG-BAC transgenic Th1 cells, although at reduced levels 
than observed at the endogenous mouse locus (Figure 2-9), consistent with reduced IFNG 
expression levels (Figures 2-1 and 2-2).  
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Figure 2-9 Relative aceylation between the endogenous mouse Ifng locus and the human 
IFNG locus.  
IFNG-BAC CD4+ T cells were cultured for three days under Th1 conditions and 
processed for chromatin immnocprecipitation assays with antibodies specific for normal 
rabbit IgG or H4Ac marks. Results are presented as fraction of input of DNA as 
determined from a standard curve and the average of three independent experiments. 
Error bars are s.d.  
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We performed H4Ac ChIP assays on day 3 CD4+ Th1 cells from Δ4, Δ3/4, Δ-30 and 
IFNG-BAC transgenic mice.  Deletion of any of the distal regulatory regions examined 
did not abolish H4 acetylation at the remaining CNS across the human IFNG locus 
(Figure 2-10A). While a paired-ANOVA test demonstrated significant difference 
between the H4Ac values between the different groups (p < .01), a control t-test did not 
identify any significance at any exact genomic position.  Further, H4Ac levels between 
BAC transgenic lines in CD4+ Th1 cells did not absolutely correlate with human IFNG 
mRNA levels in day three Th1 cells. For example, the Δ3/4 deletion did not significantly 
affect H4Ac at any specific location but completely abrogated human IFNG mRNA 
production by day three Th1 cells. Conversely, the Δ4 deletion resulted in up to a ten-fold 
increase in human IFNG mRNA, compared to IFNG-BAC transgenic controls. But, 
H4Ac levels across the IFNG locus in Δ4 Th1 cells were not ten fold above H4Ac levels 
in BAC transgenic Th1 cells (Figure 2-4F).  
 We next sought to determine if distal regulatory elements functioned to remove a 
repressive histone mark. The di-methyl histone-three, lysine 9 histone mark is thought to 
mark gene repression in mammalian euchromatin (37). CD4+ T cells develop this mark 
during both Th1 and Th2 cell polarization, but subsequently lose the mark after three 
days of Th2 polarization (108). We preformed ChIP assays from day three Δ3/4 or IFNG-
BAC Th1 cultures. H3K9Me2 levels did not vary significantly (p=0.13 by ANOVA) 
between Δ3/4 and IFNG-BAC T cells (Figure 2-10B). While these negative results do not 
rule out a role in establishing histone acetylation and methylation throughout the IFNG 
locus, we next considered that the -92 to -18 kb (Δ3/4) region and specifically CNS-30 
functioned to recruit components necessary for transcription to IFNG. To test this 
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hypothesis, we preformed ChIP assays for RNAP II on day three Δ3/4, Δ-30 and IFNG-
BAC Th1 and Th2 cells. RNAP II was recruited predominantly to the IFNG-BAC 
promoter, CNS-16, and CNS-30 in Th1 cells.  In contrast, RNAP II recruitment to the 
IFNG promoter and the CNS-16 sites was significantly reduced in Δ3/4 and Δ-30 Th1 
cells, compared to IFNG-BAC Th1 cells (Fig 2-10C). Taken together, these results 
indicate that CNS-30 is necessary for efficient RNAP II recruitment to the IFNG locus in 
Th1 cells, but is not absolutely necessary to establish histone 'marks' across the locus.  
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Figure 2-10. CNS-30 is necessary for Pol II recruitment to the IFNG locus.  
Δ3/4, Δ-30, Δ4 or IFNG-BAC CD4+ T cells were cultured for three days under Th1 
conditions and processed for ChIP assays with antibodies specific for normal rabbit IgG 
or (A) H4Ac marks (B) H3K9Me2 marks (C) Pol II. Results are presented as fraction of 
input of DNA as determined from a standard curve and are the average of three 
independent experiments. Values for IgG controls were less than 0.001 and were 
subtracted from means.  Error bars are s.d. Significance was determined by a Control t-
test and P < 0.025 
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Discussion 
 
Results presented here demonstrate that the IFNG-BAC transgene recapitulates 
many functions of the endogenous Ifng gene. These include high level expression, 
Th1/Th2 and Tc1/Tc2 selective expression, requirement for T-bet by CD4 and CD8 cells 
to express IFNG, responsiveness to IL-12 and IL-18 stimulation in both T cells and NK 
cells, and responses to antigen stimulation by effector CD8 T cells via a T-bet dependent 
mechanism. Thus, the IFNG-BAC transgene is capable of integrating the multiplicity of 
signals required for both differentiation and expression of effector function by three 
distinct cell lineages independent of its position of integration in the genome.  
There are two known distal regulatory elements necessary for sufficient IFN-γ 
production. Yet, their function in CD4+ T cells is non-redundant. Human CNS-16 
(mouse CNS-22) is a major binding site for the transcription factor T-bet (74). Human 
CNS-30 (mouse CNS-34) binds the transcription factor Runx3. A separate group has also 
identified CNS-34 as a site which binds a Runx family cofactor, CBFβ, and demonstrated 
that inhibition of Runx family members by a dominant negative approach markedly 
diminishes IFN-γ production in CD4+ Th1 cells (109). CNS-30 is necessary for efficient 
RNAP II recruitment to IFNG, but not absolutely required for histone acetylation 
throughout the interferon-gamma locus. Thus, a high level of cooperativity is needed 
among distal regulatory elements, which bind separate transcription factors, to achieve 
proper transcriptional control. In this model, T-bet binds to CNS-16 and provides initial 
chromatin remodeling of the Ifng locus in order to provide locus accessibility to Runx3 
and other transcription factors such as Hlx (105). Second, binding of these auxiliary 
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transcription factors to their own distal regulatory elements are necessary to promote 
recruitment of members of the basal transcription complex, such as RNAP II to the locus. 
Removal of distal regulatory elements from -18 to -92 kb of the IFNG 
transcription start site does not completely eliminate IFNG locus H4Ac, even though 
removal of these regulatory elements markedly interferes with IFNG transcription.  Other 
groups have proposed that CNS-4 (99), or the mouse homolog CNS-6 (76), responds to 
an early signal in effector Th1 cell differentiation to promote histone acetylation 
throughout the interferon-gamma locus. Two recent studies have shown CNS located -63 
kb, +1.5 kb and +119 kb from the IFNG transcription start site participate in formation of 
chromatin loops by binding the chromatin insulator CTCF (110, 111). In this model, 
CNS-63 and CNS+119 shield the IFNG locus from neighboring chromatin and regulatory 
elements. However, Δ4 transgenic T-cells, which lack both CNS-63 (within Δ4) and 
CNS+119 (not in the IFNG-BAC transgene), produce robust quantities of human IFN-γ 
in a Th1/Th2 specific and stimulus-specific manner, demonstrating that these distal 
CTCF binding sites are not required for cell-type and stimulus specific gene expression.  
CNS-30 is a distal regulatory element necessary for human IFN-γ production by 
T-cells and NKT cells, but not natural killer cells. The mouse homolog of human CNS-
30, CNS-34, develops histone acetylation upon Th1 differentiation, but is not acetylated 
in freshly isolated or cultured NK cells (77). CNS-34 binds the transcription factor 
Runx3, which is necessary for sufficient Ifng production in Th1 cells (105), but not in NK 
cells (106). In contrast to the cell-type specific function of CNS-34, previous studies have 
identified mouse CNS-22 (the homolog to human CNS-16) as a distal regulatory element 
necessary for IFN-γ production in T cells and NK cells (74). Unlike CNS-34, CNS-22 is 
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acetylated in NK cells (77). As such, CNS-22 is a distal regulatory element necessary for 
IFN-γ production in cells which participate in both innate and adaptive immunity, while 
CNS-34 (human CNS-30) is a regulatory element only necessary in T cells, but is 
dispensable in innate immune cells (Figure 2-11).  
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Figure 2-11 Regulatory regions within the IFNG locus possess diverse functions and 
display cell type utilization. 
The -92 to -56 kb region contains repressive distal regulatory elements, while the -56 to -
16 kb region contains necessary distal regulatory elements. In contrast, CNS-30 is a distal 
regulatory element necessary in T cells, including NKT cells, but not natural killer cells, 
macrophages and dendritic cells. The mouse homolog of CNS-16 is necessary for IFN-g 
production by T cells and NK cells (Hatton et al, Immunity 2006). Evolutionary mouse 
Human sequence conservation within the 190 kb human IFNG-BAC transgene is shown 
as identified using the dcode website (www.dcode.org). 
58 
 
 
The ability of myeloid cells to express interferon gamma is controversial (112). In 
the mouse, the identity of which exact dendritic cell subset produces IFN-γ has not been 
consistent throughout various reports (113-115). Further, mouse CD11c+ and CD11b+ 
NK cell subsets have made the identification of an IFN-γ producing dendritic cells 
difficult (107, 116). To our knowledge, human IFN-γ producing dendritic cells have not 
been described. Therefore, to understand the possible extent for cell-type specific cis-
regulatory elements, we determined which IFNG-BAC CD11c+ and CD11b+ cells were 
capable of producing human IFN-γ. Between IFNG-BAC transgenic CD11b+ and 
CD11c+ populations, IFN-γ expression is detectable within the MCH II- NK cell 
populations. Despite PMA/Ionomycin stimulation, human IFN-γ was close to background 
in MHC II+ populations. Human IFN-γ expression was very low in CD11c+, B220+, 
MHC II+ cells, which contain “Interferon-Producing Killer Dendritic Cells” (115). We 
also did not detect human IFN-γ among CD11c+, CD8+ cells, which have been reported 
to produce IFN-γ (113). Therefore, human IFN-γ, in IFNG-BAC mice, is expressed in T 
cells, NKT cells and NK cells. Unlike in CD4+ and CD8+ T cells, in MHC II-, CD11b+, 
CD11c+ NK populations, human IFN-γ is predominantly expressed in the mouse IFN-γ 
negative population. These results further substantiate cell-type specific regulation of 
IFNG.   
Mice carrying IFNG-BAC transgenes without the +20 kb to +93 kb regions (Δ1 
and Δ2 mice) were capable of producing human IFN-γ in CD4+ and CD8+ T cells. 
Because these areas contain conserved non-coding sequences, which are by definition 
implicated in fitness, we consider it likely the +20 kb to +93 kb region has a role in 
regulating IFNG. Future work will focus on the +20 kb to +93 kb region. It is possible 
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that there are elements within this region with cell-type specific roles in NK cells, where 
the -92 to -18 kb region is dispensable. Alternatively, there may be unique roles for 
regulatory elements in vivo. For example, CNSs within the IFNG locus could have tissue 
specific, or even pathogen specific, function. Both spontaneous and antigen-specific 
human IFN-γ expression in endogenous tissues will be examined in future studies.  
These results demonstrate that distal regulatory elements of a human gene 
function in a cell-type specific manner. This attribute of human gene regulation is 
recapitulated in the mouse genome. In the mouse Th2 cytokine locus, CNS-1 is necessary 
for IL-4 production in Th2 cells but not in mast cells (117). Other regulatory elements 
within the IL-4 locus do not show cell type specificity (118). Thus, different distal 
regulatory elements have varying cell-type specific functions (IFNG CNS-30 and mouse 
Th2 CNS-1) or alternatively have general function (mouse Ifng CNS-22 (74)). This 
modular use of distal regulatory elements in the mammalian Th2 cytokine and IFNG loci 
is similar to what has been found in studies of Drosophila promoters, where modular 
elements of gene promoters can function independently to direct cell-type specific 
expression (119, 120). Thus, metazoan developmentally regulated genes, in which 
expression is restricted to more than one cell-type, utilize modular distal regulatory 
elements with cell-type specific regulatory elements in possible conjunction with 
regulatory elements that function in multiple cell types.  
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CHAPTER III 
 
Expression of IFNG and IL26 requires shared and distinct cis-regulatory elements 
 
Abstract 
 
Although synteny of IFNG and IL26 genes is preserved from zebrafish to humans, 
these genes are expressed by opposing CD4 T helper cell lineages.  We show that the 
mouse Ifng locus lacks Il26 due to the insertion and serial duplication of a Cdc5l 
retrotransposon pseudogene.  We employed a bacterial artificial chromosome transgenic 
system to define functional requirements for correct expression of IFNG and IL26. 
Surprisingly, both IFNG and IL26 display Th1/Th2 selective expression, have promoters 
that bind STAT4, possess promoter T-box binding sites and share functional 
requirements for cis-regulatory elements, CNS-30 and CNS-4.  Th17 differential 
expression is achieved because both genes also employ unique cis-regulatory elements, 
CNS-16 for IFNG regulation and CNS-77 for IL26 regulation. We assessed necessary 
roles for each CNS: CTCF binding CNS+120 and CNS+20 do not have roles in the 
IFNG-BAC transgenic system. CNS-4 is needed only for Th1 and NK cell effector 
function. CNS-16 is an IFNG repressive element, but only utilized in T cell receptor 
signaling. As such, we establish one IFNG/IL26 locus where correct expression of each 
gene is established by the collaborative roles of many non-redundant cis-regulatory 
elements.  
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Introduction 
 The adaptive immune system must respond to varying classes of challenges such as 
intracellular infections or infections by extracellular bacteria and fungi. These responses 
are orchestrated by CD4+ Th1 or Th17 cells, respectively (54). The Th1 response is 
characterized by the production of interferon gamma (IFNG) by Th1 cells, CD8+ 
cytotoxic T cells and natural killer (NK) cells.  The cytokine profile of the Th17 response 
is far more heterogeneous (54). Human Th17 cells are characterized by the production 
interleukin 17, but also produce IL-22 and IL-26 (55).  Human Th17 cells also produce 
IFN-γ.  In human Th17 cells, IL17 and IL22 are preferentially expressed by IFN-γ 
negative cells while IL26 is preferentially expressed by IFN- γ positive, IL-17F negative 
cells (56). 
The IFNG gene borders the two genes IL26 and IL22.  This synteny is conserved 
from humans to Xenopus and zebrafish (82, 121). However, IL26 and IL22 are both IL10 
family members and are not structurally related to IFNG implying they possess distinct 
functions. The function of IL22 is established and this cytokine plays a key role in 
epithelial defense (122, 123). The function of IL26 is often assumed to be similar.  
However, it is known that the IL-26 protein binds to a unique receptor complex (124, 
125). In immortalized epithelial cell culture, IL-26 is thought to promote inflammatory 
cytokine expression (126). Polymorphisms within the IFNG/IL26 region are associated 
with increased risk of ulcerative colitis by genome wide association (4) and IL26 and 
IL22 are expressed at high levels in colonic and psoriatic sites of inflammation (55, 126), 
implicating a central role in inflammatory diseases of the human epithelium. However, 
mice lack an Il26 gene and its function, in vivo, is unknown. 
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In human Th1 cells, the IL26 gene loops close into the IFNG gene (30), and in 
murine Th1 cells, the Il26 pseudogene loops into the Ifng gene (111). These data raise the 
possibility of one common IFNG/IL26 locus, similar to the Th2 locus or the IL17A/F 
locus. However, an IFNG/IL26 locus would be a Th1/Th17 locus and not explained with 
current understanding of IFNG cis-regulation. IFNG depends upon noncoding sequences 
for both cell-type and stimulus specific expression. IFNG is expressed when mature Th1 
cells receive T-cell receptor signaling (72, 127). In direct contrast, CD4+ Th2 cells or 
Th17 cells must specifically repress IFNG transcription in response to identical T-cell 
receptor signaling. Transgenic mice carrying an 8.6 kb IFNG reporter transgene fail this 
developmental decision (98). In contrast mice carrying a 190 kb transgene correctly 
recapitulate repression in Th2 cells showing that IFNG requires cis-regulatory elements 
for cell-type selective expression. A 190 kb IFNG transgene also recapitulates other key 
aspects of IFNG regulation, such as stimulus-specific expression following coordinated 
stimulation by IL-12 and IL-18 (Chapter II), and specific expression in cytotoxic CD8+ T 
cells and natural killer cells. While regulation of IFNG requires cis-regulatory elements, 
precisely which cis-regulatory elements are required for individual aspects of IFNG 
regulation is incompletely understood.  
 Transcription factors T-bet (74, 77), STAT4 (77), STAT5 (76, 99), NF-κB family 
members (128), and Runx3 (129) positively regulate IFNG expression and directly bind 
to distinct conserved non-coding sequences of the mouse Ifng locus in a Th1 and stimulus 
dependent manner. Transcription factor binding is accompanied by Th1-specific covalent 
histone modifications at conserved noncoding sequences (67, 73, 128). These 
observations have led to the hypothesis that proper regulation of interferon gamma is 
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conferred by transcription factor interactions with CNS. In transgenic model systems, a 
CNS -30 kb (CNS-30) from the IFNG start site is needed for IFNG production in T cells 
(129), and a mouse CNS homolog to CNS-16 is needed for reporter expression from the 
mouse Ifng locus (74). In transient reporter assay systems mouse homologs of CNS+20, 
CNS-4, CNS-16 and CNS-30 all display enhancer activity (67, 75, 79). Lastly, CNS at 
+120 and -63 bind the chromatin looping/insulator protein CTCF (30) and are sites of 
chromatin looping of the IFNG locus. However, our understanding of function in the 
setting of an intact genome is incomplete. Two non-exclusive hypotheses could be made 
about CNS function. First, CNS may have redundant function where each CNS is 
necessary for a fraction of IFNG expression in all responder cell types in response to 
diverse stimuli.  An alternative hypothesis is that CNSs possess unique functions such 
that each individual CNS provides a unique contribution to developmental decisions and 
stimulus-specificity to achieve proper IFNG transcriptional regulation.   
To define CNS function within the IFNG/IL26 locus we employed an IFNG-
bacterial artificial chromosome model system (98, 129). In this model, mice are created 
with a transgene that contains IFNG, IL26 and surrounding regulatory regions with or 
without a specific CNS. The normal mouse production of IFN-γ is not affected, and 
serves as a control. IL26 is expressed by IFNG-BAC Th17 cells, but also displays 
Th1/Th2 selective expression. We find both that individual CNS’s confer very selective 
aspects to IFNG/IL26 cis-regulation and for some stages of IFNG expression there is 
functional overlap between CNSs.  We also find that activity of individual CNS is 
required for expression of both IFNG and neighboring IL26.  Thus, two adjacent and 
oppositely expressed genes can share a single CNS. 
64 
 
 Materials and Methods 
 
Mice and Preparation of transgenic reporter lines  
C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME), housed in 
the Vanderbilt University animal facilities, and used between 4-5 weeks of age. 
Preparation of human IFNG-BAC transgenic lines was preformed as described in chapter 
II. Briefly, human IFNG-BAC CTD-3002C24 was used to make 210 kb IFNG-BAC 
mice. Alternatively, CTD-3002C24 was moved into EL250 E. coli and CNS deletion was 
achieved using homologous recombination followed by FRT-mediated removal of the 
selection marker. Targeting primers are described in Table 3-1. Transgenic mice were 
prepared by standard pronuclear injection using circular BAC DNA, which is effective 
for generating transgenic founders (101). We used human-specific PCR primers to verify 
insertion integrity of the different IFNG-BAC transgenes. Lines without full-length 
insertions were excluded from analysis.  All animal studies were approved by the 
Institutional Animal Care and Use Committee of Vanderbilt University. 
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  Primer name / 
Plasmid name 
Targeting Primer sequence 
 
Location 
(hg18) 
Mouse 
homolog (mm8)
Δ-16 Δ -16 Forward GCAGCAAATCAGCATAGCACACATTTA
CCTATGTAACAAACCTGTACATCGAAG
TTCCTATTCTCTAGAAAGTATAGGAACT
TCAGATCTATGATTCCCT 
chr12: 
66855250-
66856250 
chr10: 
117822073-
117822727 
 Δ -16 Reverse 
 
TGAGAAAAACATCTGGTAAGGTTATTC
AGACCACTCAGCTTCATATGGATGAAG
TTCCTATACTTTCTAGAGAATAGGAACT
TCAAGCTTATGATGATGA 
  
Δ-4 Δ -4 Forward  CCAACCTGACTTCATGGACATGCAACC
TGTGCAGTCTGACAGGACCCTGAGAA
GTTCCTATTCTCTAGAAAGTATAGGAA
CTTCAGATCTATGATTCCCT 
chr12: 
66843300-
66844299 
chr10: 
117838122-
117839078 
 Δ -4 Reverse  TGATTGTACTGTGTAAGTAGCATACCT
TCTATATTCTTTGAACCACTCCTGAAGT
TCCTATACTTTCTAGAGAATAGGAACTT
CAAGCTTATGATGATGA 
  
Δ+20 Δ +20 Forward:  CCACAGAACCTGAAGCCTCCCCCTGG
AAACTTGATTATTTCAGAATCAAGGAA
GTTCCTATTCTCTAGAAAGTATAGGAA
CTTCAGATCTATGATTCCCT 
chr12: 
66855250-
66856250 
chr10: 
117822073-
117822727 
 Δ +20 Reverse 
 
GTGGGTTAGGGGCACCAGGAATTCTG
GGTAATTGGGGCTTAGCTATTTTTGAA
GTTCCTATACTTTCTAGAGAATAGGAA
CTTCAAGCTTATGATGATGA 
  
Δ-30 Δ -30 Forward TATAATTTAGAGTTAGCCTTTGAAATAA
CTTATAGAAAGCATTAATTGATGAAGTT
CCTATTCTCTAGAAAGTATAGGAACTT
CAGATCTATGATTCCCT 
chr12: 
66869614-
66870500 
chr10: 
117809759-
117810486  
 Δ-30 Reverse ATGAAGCAGAGCTAGAAAAGTGTATTA
TTAATGAAGAAGAAGAAAAACAAGAAG
TTCCTATACTTTCTAGAGAATAGGAACT
TCAAGCTTATGATGATGA 
  
Δ-77 Δ -77 Forward CATCCAAATAAAATCTGACCTTGTGTTT
TCAAAGCCCATCCCACAGGATCGAAGT
TCCTATTCTCTAGAAAGTATAGGAACTT
CAGATCTATGATTCCCT 
chr12: 
66917565-
66918546 
chr10: 
117616708-
117617782 
 Δ -77 Reverse 
 
CCCTATTTACTCTTCTTCCCCCTTCCAT
TTCCCGCCCCTCCCCAACTCCCGAAGT
TCCTATACTTTCTAGAGAATAGGAACTT
CAAGCTTATGATGATGA 
  
190 kb 
BAC 
RPCI11-
444B24 
 chr12: 
66740833-
66931792 
chr10: 
117609673-
117903582 
210 kb 
BAC 
CTD-3002C24  chr12: 
66705776-
66923225 
chr10: 
117614646-
117925027 
Table 3-1.  Primer sequences used to prepare BAC deletions and deletion locations. 
The primers used for amplifying FRT-Tet-FRT cassettes for deletion engineering and the 
locations of the BAC deletions and the entire BAC transgenes are listed below.  The first 
50 nt at the 5’ end of each primer are homology sequences for recombination, while the 
remaining 3’ nt are the annealing sequences for PCR amplification of the FRT-Tet-FRT 
cassette. Please note, figures are “flipped” in regard to absolute genomic location so that 
the beginning of the IFNG gene appears on the left of the figure. Genomic locations are 
based on March 2006 (NCBI36/hg18) assembly. 
 
66 
 
Cell Purification and Cultures  
CD4+ and CD8+ T cells were purified from splenocytes by positive selection per 
manufactures instructions (Miltenyi Biotec).  T cells were cultured with plate bound 1 
μg/ml anti-CD3 (hybridoma 2C11, American Type Culture Collection, Manassas, VA) 
and anti-CD28 (hybridoma 2C11, ATCC, Manassas, VA). For Th1/Tc1 cultures, cells 
were cultured with 10 ng/ml IL-12 and 10 μg/ml anti-IL4 (11B11 hybidoma, ATCC). For 
Th2 cultures, CD4+ T cells were cultured with 20 ng/ml IL-4 and 10 μg/ml anti-IFN-γ 
(hybridoma, ATCC). For Th17 cultures, CD4 cells were cultured with 10 ng/ml IL-1β, 20 
ng/ml IL-6, 10 ng/ml IL-23, 1 ng/ml TGFβ and 10 μg/ml anti-IFN-γ. For assays of resting 
cells, cultures were harvested on after three days and re-plated in IL-2 containing media 
for two additional days. Rested cells were restimulated with plate bound anti-CD3, 10 
ng/ml IL-12 and 10 ng/ml IL-18, 10 ng/ml IL-12 and 10 ng/ml IL-2, or 50 ng/ml PMA 
and 1 μM ionomycin.  DX5+ NK cells were purified from spleen by positive selection 
(Miltenyi Biotech).  
 Blood was obtained from healthy donors. All participants provided written informed 
consent and studies were approved by the Vanderbilt Institutional Review Board. 
Peripheral blood mononuclear cells (PBMCs) were purifed by centrifugation in a Ficoll–
Hypaque gradient (GE Healthcare Systems).  Cell sorting for CD4+ cells was preformed 
using positive selection as per manufactures’ instructions (Miltenyi Biotech). Human 
cells were cultured with plate-bound anti-CD3 (OKT3 clone, ATCC), human polarizing 
cytokines and processed for analysis identical to murine cultures conditions.  
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Intracellular cytokine staining   
T cell cultures were harvested on day four and restimulated with 50 ng/ml PMA and 1 
μM ionomycin for two hours followed by addition of GolgiPlug (130) and culture for an 
additional four hours. Cells were washed twice in ice-cold FACS buffer (2% FCS, 0.1% 
NaN3 in PBS) and labeled with fluorescent antibodies for 30 minutes as outlined in the 
results section. Cells were permeabilized and fixed with Cytofix/Cytoperm (BD 
Biosciences) according to the manufacturer’s instructions. Flow cytometric experiments 
were performed in the VUMC Flow Cytometry Shared Resource.  T cell cultures were 
gated on CD4+ or CD8+ subsets for analysis.  
 
Quantitative RT-PCR  
Total RNA was purified from restimulated Th1, Th2 and Th17 cultures and cDNA 
was synthesized using Super Script III First-strand synthesis, as per manufacture’s 
instruction (Invitrogen). Specific transcripts were quantified using TaqMan pre-made 
assays as per manufacture’s instructions (Applied Biosystems). Relative change in 
transcript levels were determined using the delta Ct method.  
 
Transient transfection assays  
The IFNG-luciferase plasmid was purchased from Addgene, plasmid number 17598. 
CNS-77 or ΔNF-κB CNS-77 was PCR amplified from RPCI11-444B24 (Invitrogen, 
Carlsbad, CA) and moved into a Pac I site of the IFNG-luciferase plasmid. Jurkat cells 
were transfected with 5 μg plasmid by electroporation. After an overnight rest, cells were 
stimulated with PMA/ionomyocin for 24 hours. Primary splenocytes were transfected 
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with 2.5 μg of luciferase plasmids using Amaxa mouse T cell nucleofector kits (Lonza). 
Cells were rested 3 hr and stimulated over night with 2 μg/ml plate-bound anti-CD3, 2 
μg/ml anti-CD28, 10 ng/ml IL-12 and IL-2. 
 
Conservation and chromatin mapping  
Mapping of ChIP-seq and DNase-seq was performed using the UCSC genome 
browser (http://genome.ucsc.edu). Data were acquired from previous experiments on 
whole CD4+ T cells (37, 39, 43, 128, 131) using the Geo database 
(http://www.ncbi.nlm.nih.gov/geo/) and 
(http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcell.aspx) for histone methylation 
marks. Multi-species locus conservation and alignments were mapped using the UCSC 
browser alignments, hg18. Transcription factor binding site prediction and genome 
alignments were preformed using the rVISTA Mulan program (132) 
(http://mulan.dcode.org/) with pre-aligned genomes. Comparison of synteny was 
performed using the rVISTA Mulan interface, with previously aligned sequences 
downloaded from the UCSC genome browser.  
 
Results 
 
IL26 and IFNG share conserved promoter elements and STAT4 binding sites 
The IFNG and IL26 gene locus is conserved in most species, but Il26 is absent in 
C57BL/6 mice. Mice are important models of human immunology, so we first 
determined the nature of the Il26 disruption in C57BL/6 mice. Analysis of sequence 
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conservation showed that the IL26 sequence was conserved throughout mammals, 
including mice (Figure 3-1). When we compared conservation of genomic order, we 
observed that in C57BL/6 mouse genome the Il26 region was disrupted due to a large 
duplication and inversion of the Il22 gene, Il26 start site and surrounding regulatory 
region (Fig 3-2, Figure 3-1A). Bordering the Il22 duplicated region, we found a mouse-
specific intrachromosomal crossover event (Figure 3-2), with serial duplications of all but 
the first 150 base pairs of the cell division cycle 5-like (Cdc5l) exons and L1 transposable 
elements. These processed pesudogenes are thought to arise when a mature transcript 
becomes incorporated into an L1 transposable element, and are typically not expressed 
(133).  The Il22 duplication and serially duplicated Cdc5l processed pesudogenes were 
not found in the rat genome and the Cdc5l pseudogenes showed up to 97.8% sequence 
identity to the mouse Cdc5l transcript but only up to 94.3% identity to the rat Cdc5l 
transcript (Figure 3-2) suggesting a mouse-specific chromosomal disruption. These data 
were consistent with a duplication of Il22 in some strains of mice, including C57BL/6 but 
not BALB/c and parental DBA/2 (134).  However, a sequence gap in the published rat 
genome covering the Il26 region prevented further analysis. Mouse CNS-54 was 
homologous to the end of the human IL26 gene. As such, the Il26 pseudogene gapped the 
duplication and cross-over event, leaving two oppositely facing start sites and numerous 
Cdc5l processed pseudogenes. 
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Figure 3-1 Comparison of human and mouse interferon gamma loci. 
 A, Locations of IFNG locus genes and STAT4 binding (135) were compared between 
the (Top) human locus and (Bottom) C57BL/6 mouse locus. Alignments were performed 
using pre-aligned data from the UCSC genome browser. Gene and STAT4 binding 
homologs are connected by dashed lines (Middle) and alignments from mouse 
chromosome 10 to human chromosome 12 are depicted by arrows (Bottom). STAT4 
binding sites are boxed and listed as kb location relative to IFNG or Ifng. B, 
Transcription factor binding sites in human IFNG locus genes. Transcription factor 
binding consensus. 
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Figure 3-2  Comparison of the mouse Ifng locus duplications and the Cdc5l transcript. 
(A) Conservation of synteny was determined using the rVISTA Mulan program and 
Pipmaker. Alignments were uploaded from the UCSC genome browser database. The X-
axis represents position on the human genome, and Y-axis represents position on the 
compared genome. (B)  A BLAT search using DNA from the highly-conserved repetitive 
region within the mouse Ifng locus (mm9 chr10:117788436-117791287) showed high 
homology to the mouse Cdc5l exons, but not the Cdc5l intron regions. (C) Each serially 
duplicated Cdc5l transcript within the Ifng genomic region was aligned to the rat and 
mouse Cdc5l transcripts using MAFT version 6. Comparing alignment to genomic 
position (D) the Cdc5l insertions showed close sequence identity the mouse Cdc5l gene. 
Multiple duplication events appear to have occurred, with an ancestral “A” and “B” site 
duplication, followed by “C” and “D”. A large duplication, probably involving the 
duplication of Il22 to create Iltifb and the E through J sites was recent, consistent with 
strain-specific Il22 duplications. The Cdc5l repetitive duplications are flanked by ERV1 
and musHAL1 retroviral transposable elements. These data suggested that the Cdc5l 
transcript was incorporated into a retroviral transposable element after the rat-mouse split 
and repeatedly duplicated throughout the mouse lineage.  
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To further compare the human and mouse interferon gamma loci, we mapped STAT4 
binding in IL-12 stimulated mouse and human Th1 cells using published ChIP-seq data 
(135). In humans, STAT4 binding was observed at both the IL26 and IFNG promoters, 
but not the IL22 promoter (Figure 3-1A). STAT4 binding was also observed at 
established human cis-regulatory elements such as CNS-16, as well as a novel site at -22 
kb which we name human CNS-22 (hCNS-22) to avoid confusion with the mouse 
homolog of CNS-16. In mice, STAT4 binding was seen at previously established mouse 
conserved noncoding sequences (mCNSs) such as mCNS-5, mCNS-22 and mCNS-33 
and also mCNS-43, which did not have a human STAT4 binding counterpart. In addition, 
STAT4 binding was not observed at homologs of the IL26 promoter in mice. We next 
determined conserved transcription factor binding sites between humans and rabbits. We 
were able to identify conserved T-box (T-bet), STAT and AML1 (Runx3) transcription 
factor binding sites at previously established CNS, such as CNS-16 and the IFNG 
promoter, as well as at the IL26 promoter. In contrast, we did not observe conserved T-
box binding sites at the IL22 promoter. To determine if the human IL26 promoter 
contained the same transcription factor binding sites as the IFNG or IL22 promoters, we 
examined the human IFNG, IL26 and IL22 promoters for T-box binding sites. We found 
T-box binding sites at the IL26 and IFNG but not IL22 promoters (Figure 3-1B). 
Commonality between IFNG and IL26, such as STAT4 binding, T-bet binding sites and 
shared genomic space suggested IL26 might exhibit Th1-like regulation, which we 
examined next. 
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 IL26 is expressed from the IFNG-BAC transgenes 
 To determine regulation of IL26 we employed an IFNG-BAC transgenic model. 
IFNG-BAC transgenes used in this study contain both IFNG and IL26 genes and 
surrounding regulatory regions. We used two transgenic lines, a 190 kb IFNG-BAC 
transgene and a larger 210 kb IFNG-BAC transgene. We sought to determine if the 
IFNG-BAC transgene was sufficient to direct IL26 expression in CD4+ cells. 
Intracellular cytokine immunoassays using IL-26 antibodies resulted in universal 
background staining of all cells tested in multiple strains of mice and types of human 
cells, so we focused on transcript measurements. We cultured IFNG-BAC CD4+ cells 
under Th1, Th2 or Th17 polarizing conditions for three days followed by a two day rest 
in IL-2. At day five, cells were restimulated for five hours with PMA/ionomycin and 
transcript levels were determined by quantitative PCR. Elevated levels of IL26 were 
expressed in cells cultured under both Th1 and Th17 conditions relative to cells cultured 
under Th2 conditions (Figure 3-3A). Interestingly, expression of IL26 showed Th1/Th2 
selectivity. IL26 transcript levels produced by either 190 kb or 210 kb IFNG-BAC 
transgenic Th1 cells were ~5,000 fold lower than IFNG transcript levels (Figure 3-3B). 
For comparison, we also cultured human CD4+ cells from PBMC under identical Th1 
and Th2 polarizing conditions. Under these conditions, IL26 displayed identical Th1/Th2 
selectivity to IFNG. Transcript levels of IL26 in human CD4 cells were ~2,500 fold lower 
than IFNG message. As such, the IFNG-BAC transgene was sufficient to recapitulate 
certain features of IL26 transcriptional regulation as seen in human CD4 cells, such as T 
helper cell selectivity. To determine if IL26 expression impacted intestinal physiology, 
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we performed histological analysis of the colon and found no signs of spontaneous 
inflammation or abnormality in 190kb IFNG-BAC mice up to 6 months of age. Upon oral 
challenge with dextran sulfate sodium, a chemical irritant, transgenic mouse weight and 
measures of inflammation were indistinguishable from controls. As such, we focused on 
regulation of IFNG and IL26. 
 
Figure 3-3 IL26 is expressed from the IFNG-BAC transgene.  
Expression levels of  transcripts were determined after culture for three days with anti-
CD3/CD28 and polarizing cytokines, two days rest in IL-2 media, and PMA/ionomycin 
restimulation. A, Transcript levels from 190 kb IFNG-BAC transgenic Th1, Th2 or Th17 
cells. B, Comparison of IL26 expression in polarized human Th1 cells and IFNG-BAC 
transgenic Th1 cells. C, Cytokine transcript levels from Th1/Th2 polarized human CD4+ 
cells.  
75 
 
 Creation and analysis of ΔCNS-16, ΔCNS-4, ΔCNS+20 transgenic mice 
Our BAC transgene correctly recapitulates developmental and signaling-dependent 
expression of IFNG (chapter II). Based upon our conservation mapping to known mouse 
regulatory regions, we hypothesized that transcriptional regulation of IFNG and IL26 was 
conferred by CNS-77, CNS-30, CNS-16, CNS-4 and CNS+20. To test this hypothesis, 
we prepared new 210 kb BAC constructs with 1 kb deletions of CNS-4 and CNS-16 and 
a 3 kb deletion of CNS+20. We named these transgenic mice ΔCNS+20, ΔCNS-16 and 
ΔCNS-4 mice. We have previously described mice lacking CNS-30 or CNS-77 from the 
190 kb IFNG-BAC (129).  Each new line had a copy number of two, equivalent to the 
copy number of the intact BAC transgene.  Transgenic mice displayed no overt 
abnormalities, were born at Mendelian ratios and gained weight at an appropriate rate. 
Mouse IFN-γ production was consistent among different transgenic lines and not affected 
by the transgene. We analyzed transgenic 210 kb IFNG-BAC, ΔCNS-16, ΔCNS-4 and 
ΔCNS+20 cells to determine if deletion of any cis-regulatory element resulted in loss of 
appropriate cell-type or stimulus specific expression of IFNG or IL26.  
 
CNS-4 is necessary for IFN-γ production 
 We first assayed for a role for CNS-4 in IFNG and IL26 production. We cultured 210 
kb IFNG-BAC or ΔCNS-4 mice for 3 days with anti-CD3 and anti-CD28 under Th1 or 
Th2 polarizing conditions. At day 3, we measured culture levels of human (left panels) 
and mouse (right panels) IFN-γ. Mouse IFN-γ did not vary among culture conditions. 
Loss of CNS-4 did not result in a significant decrease in human IFN-γ production after 
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anti-CD3/CD28 stimulation of primary Th1 cultures (Figure 3-4A). We next tested a 
physiological stimulus by backcrossing mice onto an OT-II background, in which the 
CD4+ T cell receptor recognizes a fixed OVA323–339 epitope. We cultured transgenic 
CD4+ T cells with OVA323-339 loaded APC. Loss of CNS-4 did not result in a 
significant decrease in human IFN-γ production (Figure 3-4B). We next determined if 
CNS-4 regulated long-term stability of human IFN-γ expression. We cultured CD4+ T 
cells for 3 days under Th1 polarizing conditions and for 2 additional days in IL-2. On day 
5, we restimulated resting Th1 cells with varying concentrations of anti-CD3. Human 
IFN-γ was only detectable in CNS-4 Th1 cultures stimulated with high concentrations of 
anti-CD3 (Figure 3-4C).  Similarly, ΔCNS-4 Th1 cells did not produce human IFN-γ 
after restimulation with IL-12 and IL-18 (Figure 3-4D). Human IFN-γ was also not 
detectable in primary cultures of ΔCNS-4 DX5+ NK cells stimulated with IL-12 and IL-
18 (Figure 3-4E). These results were consistent with a requirement for CNS-4 for IFN-γ 
production dependent upon either signal strength and/or stimulation of differentiated 
effector cells.  We next restimulated ΔCNS-4 or 210 kb IFNG-BAC Th1 cells and Th17 
cells with PMA/Ionomycin and measured IL26 transcript levels. ΔCNS-4 IL26 transcript 
levels were low in both Th1 cells and Th17 cells, consistent with a model in which CNS-
4 is required for stable IFNG and IL26 expression by differentiated effector cells. Thus, 
we reasoned CNS-4 might recruit histone acetyltransferases (HAT) and 
deacetyltransferases to establish the epigenetic stability of IFNG. We mapped HAT and 
HDAC binding using published ChIP-seq data (43). Indeed, both HAT and HDAC were 
recruited to CNS-4 upon CD4+ T cell activation (Figure 3-4F).  
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Figure 3-4 CNS-4 is required for IFN-γ production by differentiated effector cells.  
A, B, IFN-γ levels of transgenic CD4+ cultured for three days under polarizing 
conditions with A, anti-CD3 and anti-CD28 stimulation or B, OT-II double transgenic 
mice stimulated with OVA323-339 and APC. C, Rested Th1 cells were restimulated with 
varying concentrations of anti-CD3 for two days. D, Rested Th1 cells were restimulated 
with IL-12 and IL-18, or IL-12 and IL-2 for two days. E, Primary DX5+ cells were 
stimulated with IL-12 and IL-18 for two days. A-E, Representative experiments are 
shown and error bars are s.d. * p < .01. F, Resting Th1 or Th17 cells were restimulated 
with PMA/Ionomycin and transcript levels were quantified relative to BAC controls. 
Results are biological replicates. G, Relative locations of Pol II, HDAC and HAT binding 
(43) and mouse-human (conservation top) or platypus-human (conservation bottom) 
conservation were downloaded and plotted by the UCSC genome browser.  
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T cell receptor signaling-mediated repression of IFNG is defective in CNS-16 mice. 
 We next determined the role of CNS-16 in IFNG and IL26 regulation.  Given known 
activity of the mouse homologue, mCNS-22, we expected CNS-16 to be absolutely 
necessary for IFNG production (74). However, in primary cultures, removal of CNS-16 
resulted in a marked increase in human IFN-γ levels in both Th1 and Th2 cell cultures 
compared to the 210 kb IFNG-BAC transgene (Figure 3-5A). Removal of CNS-16 also 
resulted in a gain-of-function phenotype in primary cultures of CD8+ T cells (Figure 3-
5B). Upon restimulation of IL-2 rested Th1 cells, levels of human IFN-γ levels were 
dependent upon concentrations of anti-CD3 stimulus indicating that loss of CNS-16 did 
not produce stimulus-independent expression and was epigenetically stable (Figure 3-
5C). We next tested stimulus-dependence. In contrast to T-cell receptor signaling, 
expression of human IFN-γ in response to IL-12 and IL-18 stimulation was not affected 
by the CNS-16 deletion (Figure 3-5D). Similarly, the Δ-16 CNS deletion did not affect 
human IFN-γ production by NK cells stimulated with IL-12/IL-18 (Figure 3-5E). When 
we analyzed IFNG and IL26 transcript levels in PMA/Ionomycin restimulated Th1 and 
Th17 cells, we confirmed a relative increase in IFNG transcript levels from CNS-16 
mice, compared to controls (Figure 3-5E). However, IL26 transcript levels were not 
different between CNS-16 and 210 kb IFNG-BAC cultures (Figure 3-5 E, F). Single cell 
analysis of PMA/Ionomycin restimulated cells showed an increase in the percentage of 
human IFN-γ+ cells in ΔCNS-16 CD4 and CD8 cells, relative to controls (Fig 3-6). To 
summarize, deletion of CNS-16 from the 210 kb IFNG transgene resulted in a gain-of-
IFNG expression phenotype in CD4+ Th1, Th2, Th17 and CD8 cells which was 
dependent upon T cell receptor signaling. We reasoned repression may involve a cell-
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type independent repressor of IFNG. The transcription factor YY1 is a constitutively 
expressed situational repressor or activator of IFN-γ (136, 137). We mapped binding of 
YY1 in resting CD4 cells and STAT4 and STAT5 binding in activated CD4 cells using 
published ChIP-seq data (131, 135). Indeed, while multiple CNS bound STAT proteins, 
YY1 binding in resting CD4 cells was restricted to CNS-16 (Figure 3-5H).  
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Figure 3-5 Loss of CNS-16 impairs Th2-mediated IFNG repression.  
A, B, IFN-γ levels of transgenic CD4+ or CD8+ T cells cultured for three days under 
polarizing conditions. C, Rested Th1 cells were restimulated with varying concentrations 
of anti-CD3 for two days. D, Rested Th1 cells were restimulated with IL-12 and IL-18, or 
IL-12 and IL-2 for two days. E, Primary DX5+ cells were stimulated with IL-12 and IL-
18 for two days. A-E, Human and murine IFN-γ levels in cultures were determined by 
ELISA. Error bars are s.d. F, G, Resting Th1, Th2 or Th17 cells were restimulated with 
PMA/Ionomycin and transcript levels were quantified relative to F, Th1 cultures or G, 
210 kb IFNG-BAC controls. H, Relative locations of STAT4, STAT5A, STAT5B (128) 
and YY1 binding (131), Th1/Th2 DNaseI-HS (UW ENCODE) and mouse-human 
(conservation top) or platypus-human (conservation bottom) conservation were 
downloaded and plotted by the UCSC genome browser. 
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Figure 3-6 Intracellular cytokine staining of CNS-16 and CNS-4 T cell cultures.  
Day five CD4+ Th1 cells or CD8+ Tc1 cells were restimulated for five hours with 
PMA/Ionomyicin and IFN-γ levels were determined by intracellular cytokine staining. 
Data points are independent experiments.  
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190 kb, 210 kb, and ΔCNS+20 IFNG-BAC mice express IFNG equivalently 
 We next compared mice containing the 190 kb IFNG-BAC transgene and the 210 kb 
IFNG-BAC transgene. The two transgenes differ primarily by the absence of a +120 kb 
CCCTC binding factor site in the 190 kb IFNG-BAC. We mapped locus CTCF sites to 
our IFNG-BAC transgene using published ChIP-Seq data (39) (Figure 3-7A). Culture 
levels of human IFN-γ and murine IFN-γ did not differ between 190 kb and 210 kb 
IFNG-BAC transgenic CD4+ or CD8+ T cell cultures containing either two or three 
CTCF binding sites, respectively (Figure 3-7B, 5C). Both 190 kb and 210 kb IFNG-BAC 
transgenes demonstrated Th1/Th2 selectivity but neither was expressed at equivalent 
levels to the endogenous mouse IFNG gene (Figure 3-7C). Similarly, the ΔCNS+20 
deletion did not affect IFN-γ production by either T cells or NK cells (Figure 3-8). As 
such, we were unable to demonstrate a functional role for CNS+20 or the +120 kb CTCF 
site in our transgenic IFNG-BAC model system.  
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Figure 3-7 Two IFNG-BAC transgenes express IFNG equivalently.  
A, Relative locations of the 190 kb IFNG-BAC transgene and 210 IFNG-BAC transgenes 
used in this study, Th1/Th2 DNaseI HS-seq and resting CD4+ T cell CTCF ChIP-seq 
were mapped using the UCSC genome browser. B, 190 kb or 210 kb IFNG-BAC 
transgenic CD4+ T cells were cultured for three days with anti-CD3/CD28 under Th1 or 
Th2 polarizing conditions. At day three human and mouse IFN-γ levels in cultures were 
determined by ELISA. C, Human and mouse IFN-γ levels from day three CD8+ Tc1 
cultures. D, CD4+ Th1 cells were cultured for three days, rested for two days in IL-2 
media and restimulated with PMA/Ionomycin. Transcript levels were determined by 
qPCR after cDNA synthesis. 
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Figure 3-8  Removal of CNS+20 does not result in a significant change in human IFN-γ 
levels 
 (A) IFN-γ levels of transgenic CD4+ cells cultured for three days under polarizing 
conditions. (B) Rested Th1 cells were restimulated with varying concentrations of anti-
CD3, IL-12 and IL-18, or IL-12 and IL-2 for two days. (C) Primary DX5+ cells were 
stimulated with IL-12 and IL-18 for two days  
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CNS-77 regulates IL26 but not IFNG 
 To complete our functional analysis of the IFNG/IL26 locus, we asked whether IL26 
has unique regulatory elements separate from IFNG regulatory elements. We returned to 
transgenic mice lacking ΔCNS-77 from the 190 kb IFNG-BAC transgene (ΔCNS-77 
mice) created previously (Chapter II). We also examined ΔCNS-30 mice, which lack 
CNS-30 and express human IFNG at ten fold reduced levels to 190 kb IFNG-BAC 
transgenic T cells.  The CNS-77 deletion was identified by conservation between humans 
and mice. However, mapping of covalent histone modifications associated with active 
enhancers such as histone-3 lysine 4-methyl (H3K4Me1), H3K4Me2 and H3K4Me3 
identified two potential regulatory sites on both sides of the CNS-77 deletion (Figure 3-
9). To validate CNS-77 itself as an enhancer we cloned the CNS-77 region into a well-
characterized IFNG-luciferase vector (138). We transfected the IFNG-luciferase vector 
with or without CNS-77 into primary BALB/C splenocytes, cultured with anti-
CD3/CD28 for three days and measured luciferase activity after PMA/Ionomycin 
restimulation (Figure 3-9C). Inclusion of CNS-77 resulted in a relative increase in 
luciferase activity demonstrating the presence of enhancer function.  Next, we identified 
two NF-κB binding sites within CNS-77. To test for NF-κB dependence, we removed one 
of these binding sites in a new CNS-77 IFNG-luciferase construct.  We transfected Jurkat 
T cells with the three different luciferase constructs and, after recovery, restimulated with 
PMA/ionomycin.  Deletion of one NF-κB site abrogated enhancer function (Figure 3-
9D).  Having Nf-kB dependent established enhancer potential, we continued with our 
analysis of ΔCNS-77 mice to determine function in a genomic setting. 
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Figure 3-9  IL26 expression in ΔCNS-77 and ΔCNS-30 CD4 cells 
A, Locations of genes, covalent histone marks (37) and STAT4 binding (128) sites were 
downloaded and mapped using the UCSC genome browser. B, Diagram of IFNG-
luciferase reporter plasmids. C, BALB/C splenocytes were transfected with IFNG-luc or 
CNS-77•IFNG-luc reporter plasmids. Luciferase activity was determined after 24-hour 
stimulation with anti-CD3 and anti-CD28. D, Jurkat cells were transfected with luciferase 
constructs and after overnight rest stimulated with PMA/ionomycin for four hours and 
luciferase activity was determined. Data points are biological replicates of seven 
independent experiments. E, Rested 190 kb IFNG-BAC, ΔCNS-30 or ΔCNS-77 IFNG-
BAC CD4+ Th1 cells were restimulated with PMA/ionomycin and transcript levels were 
determined by qPCR. F, Transcript levels of IL26 in Th17 cells. Data points are 
biological replicates of three experiments.  
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  To determine if either CNS-77 or CNS-30 was required for IL26 expression from the 
190 kb IFNG-BAC we restimulated resting 190 kb IFNG-BAC, ΔCNS-30 or ΔCNS-77 
Th1 and Th17 cells with PMA/Ionomycin and measured transcript levels (Figure 3-9 E & 
F). As previously reported, CNS-30 was required for IFNG transcription in restimulated 
Th1 cells.  CNS-30 was also required for IL26 transcription by both Th1 cells and Th17 
cells. Deletion of CNS-77 did not alter IFNG transcript levels in Th1 or Th17 cells, but 
removal of CNS-77 resulted in a marked loss of IL26 transcripts.  Combining these 
results with results from CNS-4, CNS-16 and CNS+20 deletions, we conclude that CNS-
4 and CNS-30 deletions had multi-gene phenotypes, impacting both IFNG and IL26 
expression. CNS-77 and CNS-16 deletions had single-gene phenotypes, regulating just 
IL26 or IFNG, respectively.  
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Discussion 
 
 Here we have determined the functional roles of cis-regulatory regions throughout the 
IFNG/IL26 locus using a BAC transgenic system (Figure 3-10). We have demonstrated 
that IFNG and IL26 share common regulatory elements in surprisingly both Th1 cells and 
Th17 cells, demonstrated that loss of one distal CTCF site in the IFNG locus is not 
required for efficient transcription, and defined specific functional roles of conserved 
IFNG/IL26 regulatory regions. We demonstrate that CNS-4, CNS-16, and CNS-30 play 
key roles in regulating IFNG expression. We show that IFN-γ production in response to 
either T cell receptor signals or cytokine signaling requires distinct cis-regulatory 
elements. Th1/Th2 specificity is not solely dependent upon activating Th1 enhancers but 
also requires Th2 specific repressors, as evidenced by a lack of complete IFNG 
repression in Th2 cells lacking CNS-16. We have identified cis-regulatory elements 
necessary for only IFNG or IL26 expression and alternatively identified cis-regulatory 
elements whose function is shared between both IFNG and IL26.  
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Figure 3-10 Summary of IFNG-BAC CNS deletion phenotypes.  
Plotted are relative locations of Th1 DNase-HS sites, labeled with function in an IFNG-
BAC transgene. Each CNS is listed with what gene it is required for, and a short 
description of what cell type and/or stimulus it is required for. The summary for CNS-30 
includes previous results (129). 
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A particularly novel finding is that expression of both IL26 and IFNG requires CNS-
30 and CNS-4 and both show Th1/Th2 selectivity, establishing an IFNG/IL26 gene locus. 
The IL26 promoter closely resembles the IFNG promoter, but not the IL22 promoter in 
that the IL26 promoter contains T-box binding sites and is a site of STAT4 recruitment. 
However, IL26 also exhibits distinct expression from IFNG and is upregulated in Th17 
cells. Distinct regulation of IFNG and IL26 is accompanied by distinct cis-regulatory 
elements for each gene. IFNG requires CNS-16 for Th1-specific expression and IL26 
requires CNS-77 for transgenic expression in both Th1 and Th17 cell types. How the 
IFNG/IL26 locus integrates information for coordinated repression and/or activation of 
IFNG and IL26 will be a subject of future investigation.  Expression of IL26 in both 
human and mouse T cells was low. Further, currently available reagents prevented 
meaningful analysis of IL-26 protein expression. Therefore, it is not clear if there are Th1 
IL-26+ cells and/or Th17 IL-26+ cells. It is also currently not clear exactly what specific 
cell types, if any, express IL26 at abundant levels. Further, the in vivo function of IL26 is 
currently unknown due, in part, to absence of mouse models. The IL26 and IFNG locus is 
a candidate locus for ulcerative colitis risk (4). However, this risk association has not 
been mechanistically linked to either gene. Further, transgenic expression of human IL26 
does not cause spontaneous inflammation in a mouse model, or impact severity of DSS-
induced colitis. Future studies will also focus on determining the function of IL26 in the 
immune system.   
 One surprising finding is the requirement of CNS-16 for T cell-receptor mediated 
repression of IFNG in Th2 cells. A similar phenotype is seen in transgenic mice carrying 
only an 8.6 kb IFNG transgene, in which Th2 cells do not repress IFNG in response to T 
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cell-receptor signaling (98). One hypothesis is repressive function is conferred by the 
recruitment of YY1, which represses IFNG expression (137). Alternatively, CNS-16 may 
function to recruit repressive HDAC proteins. In mice, recruitment of HDACs to the 
CNS-16 homolog is critical for proper suppression of Ifng (44). However, in a similar 
BAC transgenic system, the murine CNS-16 homolog is absolutely necessary for 
transcription of an Ifng-BAC transgene reporter (74). Given that CNS-16 is not conserved 
outside of non-placental mammals and BAC transgenic expression of IFNG is possible 
without CNS-16, CNS-16 is not universally required for interferon gamma expression. 
Instead, the CNS-16 homolog STAT4 binding potential may be more critical in the 
C57BL/6 mouse Ifng locus than it is in the human locus. Our chromatin mapping and 
conservation analysis reveals a multitude of differences between the mouse and human 
locus, possibly explaining the differences in phenotypes. The human but not mouse locus 
contains hCNS-22 (Figure 3-1), which may provide additional function in the human 
genome relative to the murine genome. The mouse Ifng locus also contains wide-ranging 
structural variation including serial duplications of the Cdc5l processed pseudogene. 
Retrotransposons are well known to have regulatory effects on nearby protein-coding 
genes (139). The C57BL/6, but not BALB/c, genome also contains a large duplication 
and inversion of Il22 and the Cdc5l pseudogenes (134). Given these differences, 
comparative genomics between the C57BL/6 and BALB/c mouse Ifng loci and human 
IFNG/IL26 loci will likely provide fruitful insights into the role of species-specific 
regulatory regions and structural variation.  
 Although CNS-77, CNS-30, CNS-16 and CNS-4 exhibit necessary functions in 
regulation of IFNG/IL26 expression in our IFNG-BAC transgenic system, IFNG/IL26 
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expression does not exhibit similar requirements for CNS+20 or CNS+120. Both 
CNS+20 and CNS+120 are well conserved throughout mammals, implying function. 
CNS+120 is thought to facilitate three-dimensional organization of the IFNG locus via 
CTCF binding. CTCF has been described as a transcriptional activator (31), insulator (32) 
and repressor (33). However, most of these functional studies come from reporter assay 
systems which do not take genomic context into account and a relevant question is the 
exact function of CTCF binding sites in the genome.  In a genomic context, experimental 
mutation of a single CTCF site in the β-globin locus affects chromatin looping and 
accessibility, but not expression of the β-globin gene (34). Arguing against an insulating 
role of the +120 CTCF site in the IFNG locus are previous experiments reporting copy-
number dependence for 190 kb IFNG-BAC transgenes lacking the +120 CTCF site 
(Chapter II), and equivalent expression between 190 kb and 210 kb IFNG BAC 
transgenes. Another hypothesis would be that the +120 kb and -63 kb CTCF sites serve to 
bring the IFNG locus into close physical location with other genes in the surrounding 
regions and may play a role in co-regulation of IFNG and IL26 or may govern 
interactions between the Ifng locus and the Il4 locus (28). Like CNS+120, CNS+20 does 
not have an appreciable role in our model system. In IFNG-luciferase systems, CNS+20 
has enhancer potential (67, 79), but CNS+20 may only have necessary functions 
observable under suboptimal signaling conditions in cooperation with CNS-4. To analyze 
this hypothesis, future studies will focus on experiments, in vivo, to determine the roles of 
cis-regulatory elements in the context of infections, which suppress the immune system, 
as well as determining expression when specific transcription factors are absent.  
93 
 
94 
 
 Despite recent advances in the ability to identify cis-regulatory element location, it is 
difficult to answer basic questions about function of a cis-regulatory element such as 
what gene it regulates, in what cell type and whether it plays a repressor or activator role. 
IFNG/IL26 regulatory elements are necessary for functionally redundant roles and also 
necessary for highly specialized roles. For example, there are cell-type specific cis-
activating elements, such as CNS-30 (Chapter II), and stimulus specific repressors, such 
as CNS-16. Consistent with these results, a growing body of evidence suggests that cis-
regulation is necessary for very exact cell and stimulus specific roles (27, 140). 
Alternatively, we also identified redundant roles for cis-regulation. CNS-30 and CNS-4 
both recruit Pol II and are both required for IFNG/IL26 production in mature T cells. 
Consistent with these results, studies in Drosophila demonstrate that redundant enhancers 
provide phenotypic robustness under suboptimal conditions (141). Lastly, we find 
evidence of shared requirements for individual cis-regulatory elements between adjacent 
genes. As such, human cis-regulatory elements may be necessary for a variety of 
different functions, not currently predictable without experimental testing. The 
multiplicity of potential cis-regulatory functions may explain why it has been difficult to 
link trait associated human single polymorphisms with function (6). Our results show a 
surprisingly wide breath of function that cis-regulatory elements possess, and illustrate 
the great diversity of phenotypes that can result from cis-regulatory mutations in humans.  
 
 
 
 
CHAPTER IV 
 
Synopsis and conclusion 
 
Conclusions 
 
In this work I show that IFNG cis-regulatory elements have highly specialized roles, 
each necessary for a unique functional requirement. I also redefine the IFNG locus and 
show that it is part of a larger IFNG/IL26 locus whereby both genes utilize common 
regulatory elements to produce shared patterns of expression.  
 The major finding of chapter II is that utilization of IFNG distal regulatory elements 
is cell-type specific. Natural killer cells and cells of the T cell lineage do not have similar 
requirements for IFNG expression from an IFNG-BAC transgene. This phenotype is 
observed in two instances. First, expression of IFNG in T cells is predominately restricted 
to mouse IFN-γ positive cells, while in natural killer cells human IFN-γ expression is 
observed in mouse IFN-γ negative cells and mouse IFN-γ positive cells. A second way in 
which expression of IFNG differs between T cells and NK cells is that T cells require 
CNS-30 for proper expression of human IFN-γ. In contrast, NK cells do not require CNS-
30.  
 A second important finding of chapter II is the mechanism of action of CNS-30. 
Transcriptional regulation can occur at several stages including alterations in 
chromosomal accessibility, transcription factor recruitment, polymerase recruitment and 
polymerase initiation and elongation. It was our assumption that CNS-30 would function 
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to promote chromosome accessibility. However, removal of CNS-30 from an IFNG-BAC 
transgene does not change locus acetylation or H3K9me2, compared to controls. Instead, 
removal of CNS-30 completely prevents recruitment of polymerase showing that CNS-30 
plays a major role in late stages in the activation of IFNG.  The requirement for Pol II 
binding correlates with Runx3 binding at CNS-30 and, as shown in chapter III, STAT4 
and STAT5B binding at CNS-30 in activated T cells. As such, the coordinated action of 
Th1-promoting transcription factor binding at this distal regulatory element serves to 
permit RNA Pol II recruitment to this CNS as well as to the IFNG promoter. 
 The major finding of chapter III is that some IFNG cis-regulatory elements are not 
redundant. We had expected to find a series of cis-regulatory elements all necessary for 
IFNG expression. Instead, we found several cis-regulatory elements, which do not affect 
human IFN-γ expression from our IFNG-BAC model system, such as CNS+20 and 
CTCF binding CNS+120. Other elements have very selective functions, such as CNS-4, 
which promotes epigenetically stable expression of IFNG in mature T cells and natural 
killer cells. Loss of CNS-16 produces a phenotype opposite of expectations and results in 
aberrantly high human IFN-γ expression in T cells stimulated with T-cell receptor 
signaling, but not T cells or NK cells stimulated with IL-12 and IL-18. Functionally, 
CNS-16 appears to play a necessary role to actively repress IFNG expression in effector 
Th2 cells.  This model of highly specific distal regulatory elements is very consistent 
with the view of cis-regulation in evolution, where the acquisition of necessary cis-
regulatory elements occurs when new functions are acquired and thus cis-regulatory 
elements have very fine-tuned roles.  
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 A subsequent finding of chapter III is that IFNG and IL26 share common regulatory 
elements and expression, but also have distinct regulatory elements and distinct 
expression profiles. For example, both IFNG and IL26 exhibit relatively high expression 
in Th1 cells compared with Th2 cells. However, only IL26 is also expressed at relatively 
high levels in Th17 cells while IFNG is repressed in in vitro generated murine Th17 cells. 
Both genes contain similar promoters, with T-box and STAT binding sites. Further, the 
co- and differential expression is in part achieved by shared cis-regulatory elements and 
distinct cis-regulatory elements. In CD4+ T cells, CNS-77 is required for IL26 expression 
but not IFNG expression. Similarly, removal of CNS-16 from the IFNG-BAC transgene 
results in high IFNG expression but not high IL26 expression in response to 
PMA/Ionomycin stimulation. In contrast, both elements share CNS-4 and CNS-30 
because removal of either from the IFNG-BAC transgene prevents expression of both 
IL26 and IFNG.  
  
Future Directions 
 
Distal regulation of Interferon Gamma 
Distal regulation of the IFNG locus varies between natural killer cells and T cells. 
This result is expected in a model of functionally specific cis-regulatory elements, but 
mechanistically unclear. It may be possible to understand the differences in 
transcriptional regulation between natural killer cells and T cells from two approaches. 
Firstly, using BAC model systems additional cis-regulatory elements can be discovered 
and their roles in natural killer cells versus other T cells can be probed. This may be 
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promising in the +40 to +120 kb region of the IFNG-BAC transgene, which does not 
appear to be required for expression in T cells. This first approach stems from the 
hypothesis that natural killer cells utilize distinct cis-regulatory elements for proper 
transcription and could be verified mechanistically by examining chromatin accessibility 
and transcription factor recruitment to the IFNG locus. If true, natural killer cells should 
have distinct patterns of DNase I hypersensitivity, transcription factor and Pol II 
recruitment and covalent histone modifications.  
However, a second possible hypothesis may also explain why natural killer cells and 
T cells have different functional requirements for IFNG distal regulatory elements. In this 
hypothesis, the transcription factor population required to promote cytokine gene 
expression is fundamentally different in natural killer cells and T cells due to broad 
chromatin regulation. This hypothesis is supported by the observation that mouse natural 
killer cells express high levels of both Ifng and transgenic IFNG transcript, and other 
reports detail post-transcriptional regulation of cytokine production in natural killer cells 
(142). Under this hypothesis, a repressive transcription factor or chromatin regulation 
protein could be differently modified or expressed in T cells and natural killer cells, 
allowing easier expression in NK cells. If true, many observations such as DNaseI 
hypersensitivity and transcription factor binding may be different in NK cells than in T 
cells. So, a transgenic approach to test sufficiency rather than necessity may be 
appropriate. Further, analysis of protein expression and modification by mass 
spectrometry approaches will provide insight into effector protein differences. If natural 
killer cells have fundamentally different requirements for gene expression, understanding 
these differences will provide needed basic insight into how gene expression is portioned 
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between the innate immune system, which does not need to avoid autoimmunity, and the 
adaptive immune system, which does.  
Reports on the relationship between cis-regulatory elements and chromatin 
accessibility, Pol II recruitment and transcription factor recruitment have varied based 
upon experimental system and gene locus, as described in chapter I. In the IFNG-BAC 
transgenic system, CNS-30 is required for Pol II recruitment, but not required for locus 
histone tail acetylation or methylation. Using transgenic mice lacking CNS-30, CNS-16, 
CNS-4 and CNS+20 the relationship between distal regulation and effector protein 
recruitment and chromatin accessibility of the IFNG locus can be studied in fine detail. 
For experimental purposes transcription can be broken into four broad stages: chromatin 
accessibility, transcription factor recruitment, polymerase recruitment, and polymerase 
initiation and elongation. A fifth very poorly understood stage of nuclear positioning 
could also be added. Using chromatin immunoprecipitation techniques, the relationship 
between distal regulatory elements to each of these first four stages could be tested with 
the IFNG-BAC transgenes. For example, CNS-4 seems required for IFNG expression 
after primary stimulation. If CNS-4 is required for establishing an epigenetically 
permissive IFNG locus then histone acetylation or IFNG promoter H3K4Me3 marks may 
be absent in ΔCNS-4 Th1 cells. Secondly, using the two different 190 kb and 210 kb 
IFNG-BAC transgenes the relationship between CTCF binding sites, chromatin looping, 
insulation and polymerase initiation can be probed. Finally, the relationship between cis-
regulation and location in the nucleus is not clear. Using the different 190 kb and 210 kb 
BAC transgenes, and CNS deletions, 3D FISH technology could be used to determine if 
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transgene incorporation in to transcription factory ‘hubs’ depends upon distal CTCF sites 
and/or IFNG regulatory elements.  
 
Interleukin 26 
 The mouse Ifng locus is interrupted with serially duplicated Cdc5l retrotransposed 
pseudogenes. These pseudogenes are evolutionarily recent, with higher homology to the 
mouse than rat Cdc5l parent transcript. The Il22 gene and surrounding region is 
duplicated in some strains of mice, but not others. This duplication, by homology, 
contains Cdc5l pseudogenes. This would theoretically create varying amounts of Cdc5l 
pseudogene duplications in different strains of mice. A congenic approach could provide 
insights into the role of structural variation and retrotransposed elements in the local 
chromatin environment. Besides implications for mouse models of Ifng expression, 
structural variation has been implicated in many different oncogenic events and 
retrotransposition events are known to impact local chromatin environments by recruiting 
repressive histone modifying proteins. An Ifng locus congenic, or BAC-transgenic model 
of the Ifng locus with and without Cdc5l repetitive elements would be an excellent model 
to understand structural variation and the role retrotransposed pseudogenes play in long-
range regulation and the establishment of proper epigenetic states. Of note, mice with 
theoretically few Cdc5l pseudogenes, like BALB/c have low IFN-γ expression, while 
strains with theoretically high Cdc5l pseuodgene counts, like C57BL/6 have high IFN-γ 
expression.  
 Mice lack Il26 and this may explain why little is known about the function of IL-26 in 
both the innate and adaptive arms of the immune system. However, many genes are 
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lacking in mice and little may be known about IL-26 because IL-26 may be vestigial or of 
little importance in higher mammals. Arguing against an unimportant role in the immune 
system is the fact that IL-26 is conserved throughout the metazoan tree, arguing for some 
essential function. In tissue culture models, recombinant IL-26 promotes IL-8 and anti-
microbial peptide synthesis and release. Further, IL-26 is highly expressed in ulcerative 
colitis inflamed lesions. However it is still unclear which cell types in response to which 
stimuli produce the IL-26 protein. While the gene shares regulation with IFNG, it does 
not share high expression with IFNG in Th1 cells. Possibly, select tissues other than 
mature Th1 or Th17 cells may express IL-26. For example, inflamed epithelial cells 
produce IL-22 and may express IL26.  It may be possible to better understand IL-26 
biology with the BAC transgene system we have developed. It would first be important to 
establish that the human IL-26 protein is functional in the mouse by establishing 
expression of the IL-26 receptor in the mouse, and if recombinant human IL-26 can 
activate the mouse IL-26 receptor. In a DSS colitis experiment, the IFNG-BAC transgene 
provided protection from DSS in initial experiments, but not upon subsequent 
experiments. With refinement of experimental procedures, or with alternative models of 
colitis and inflammation, a role of IL26 in the immune system could be elucidated.  
 
 Human Polymorphisms 
In a recent genome wide association study, an ulcerative colitis associated single 
nucleotide polymorphism was identified on the IFNG locus. The more probable 
association was found in a region not containing any of the known IFNG regulatory 
elements established in my BAC transgenic model, or studied in mouse homologs. 
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Instead, the region appears devoid of IFN-γ cis-regulatory elements, other than one 
conserved noncoding region at +80 kb from the IFNG start site (Figure 4-1). CNS+80 
shows Th1 specific DNaseI HS, as well as STAT4 and STAT5B binding. However, 
CNS+80 is 30 kb from the GWAS-identified rs158744. Linkage disequilibrium is low, 
and the HapMap CEU r squared value for this region does not exceed 0.5. Further, 
rs1558744 does not have a high r squared value for any region in the established IFNG 
regulatory regions. As such, further characterization of CNS+80 and its relationship to 
rs158744 is needed, as well as associative studies between the UC-associated 
polymorphisms and cytokine gene expression. Cis-regulation is notorious for jumping 
genes, and even acting on opposing chromosomes, making analysis difficult. However, 
there is a long and controversial relationship between IFN-γ and inflammatory bowel 
disease. As such, the relationship between rs158744 and IFNG expression needs to be 
examined further.  
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Figure 4-1. The interferon gamma locus and genome wide association studies  
STAT4, STAT5B, Th1 DNaseI HS, Th2 DNaseI HS and HapMap CEU phased r2 values 
were plotted using the UCSC genome browser. Labeled SNPs are associated with 
ulcerative colitis by a genome wide association study by Sileverberg et al. While the SNP 
rs2870946 is within high linkage disequilibrium to most of the know interferon gamma 
locus, SNP rs1558744 is separated from the known IFNG locus by a recombination hot 
spot.  
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In preliminary experiments, genotype of rs158744 correlated with IFNG transcript 
level in both cultures of peripheral Th1 cells and in peripheral blood mononuclear cells. 
Increasing copies of the rs1558744 minor allele correlate with increasingly lower levels 
of IFNG transcript. As such, if rs158744 genotype can be mechanistically linked to a 
CNS+80 defect then a role of IFNG cis-regulation in ulcerative colitis pathogenesis can 
be established. Because rs158744 is common and because human T cells can be easily 
grown and manipulated ex vivo, a CNS+80 defect would be an ideal model system to 
study distal regulation in humans. A growing observation in the field of human genetics 
is that the majority of the common variation associated with disease lies in the noncoding 
segment of the genome (6). As such, understanding the non-coding segment of the 
genome will be critical for the development of novel therapeutics, tailored medicine and 
biomarkers. IFNG CNS+80 would be a prime example, as IFN-γ expression will have 
roles in many aspects of the immune system and is a viable therapeutic target. Further, as 
analysis of genetic susceptibility goes from common variants to uncommon and rare 
variants, more and more cis-regulatory elements are likely to be discovered. 
Understanding cis-regulation from a functional standpoint will be, and is currently, 
absolutely necessary to interpret human disease risk and thus treatment.  
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